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bFGF basic fibroblast growth factor
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PCR polymerase chain reaction
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mRNA messenger ribonucleic acid
ROS reactive oxygen species
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TGF-p transforming growth factor beta
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The corpus luteum is a transient endocrine gland which is essential for the
maintenance of early pregnancy in mammals. The gland persists to secrete
progesterone in the presence of hCG in early pregnancy but will regress if
conception has not occurred, allowing a new ovarian cycle to begin.
Control of the lifespan of the corpus luteum is essential for reproduction but is
poorly understood. Neither the mechanisms which allow the corpus luteum to
persist in early pregnancy nor those which limit the lifespan of the gland in non-
conception cycles are known.
Many investigators have addressed these questions in recent years, and in vitro
systems have been widely utilised to study luteal function. While studies
examining luteinised granulosa cells have yielded important physiological data
they provide a limited insight into the in vivo processes which may control luteal
function.
In order to examine luteal physiology in vivo, a system has been designed to
allow retrieval of human corpora lutea throughout closely monitored ovarian
cycles. The system has also allowed retrieval of luteal tissue from women
undergoing hormone treatment to simulate early pregnancy.
The experimental chapters of this thesis describe in detail the retrieval and
characterisation of this tissue. Investigations utilizing the tissue to study
potential control points in luteal maintenance and regression are then
described.
The following introductory paragraphs set the scene for these investigations by
describing what is already known about the structure, endocrinology and
physiology of the corpus luteum in mammals, and in particular in women.
Potential mediators of luteal maintenance and regression are discussed, with
particular emphasis on areas examined in the experimental work of this thesis;
the luteal vasculature and its growth, programmed cell death, and the immune
system.
1.1.1 Historical background.
The corpus luteum was first described by Vesalius of Padua in 1555 and the
secretory function of this tissue was acknowledged as early as 1609 when
Fabricius described corpora lutea as 'multiple joined glands' (Auletta and Flint
1988). In the 17th century the importance of the corpus luteum for reproduction
was first suggested by de Graaf who noted that in the rabbit the number of
these ovarian glandular bodies corresponded to the number of embryos (de
Graaf 1672). The term 'corpus luteum' was first used by Malphighi in 1697
(Auletta and Flint 1988). Not until 200 years later did the function of the corpus
luteum come under further scrutiny, when it was proposed that the corpus
luteum was a highly vascular gland of internal secretion (Prenant 1898). The
first report of the biological significance of the gland was published in 1903 by
Frankel who demonstrated that pregnancy was terminated in rabbits following
lutectomy. The steroidogenic potential of the corpus luteum became clear in
1929 when Corner and Allen isolated progesterone from luteal tissue.
1.1.2 Luteal structure
General points
The corpus luteum forms from the dominant ovarian follicle after ovulation. The
gland is a heterogeneous structure and is composed of different cell types
including steroidogenic cells, endothelial cells, fibroblasts and leukocytes (Azmi
et al 1984; Lei et al 1991; Gillim et al 1969). The parenchyma of the corpus
luteum exhibits infoldings around a central area of fibrin clot which develops in
place of the previous follicular antrum. External to the parenchymal cells is a
fibrous stroma which surrounds the gland and contains arterioles and venules,
fibroblasts and immune cells (Corner 1956). Between the steroidogenic cells of
the gland lie numerous small capillaries. The vascular bed of the corpus luteum
is so dense that the majority of steroidogenic cells are in contact with at least
one endothelial cell (Dharmarajan et al 1985; Zheng et al 1993; Reynolds et al
1992).
In addition to the cellular components of the corpus luteum, non-cellular
components such as the extracellular matrix may be important not only for the
structure but also for the function of the gland (Behrman et al 1993; Duncan et
al 1996a;b;c).
Non-primate species
It is widely accepted that in ungulates the steroidogenic cells of the corpus
luteum are derived from both theca and granulosa layers of the follicle
(Rothchild 1981; Fritz and Speroff 1982). These layers may differentiate after
ovulation to form small and large luteal cells (Auletta and Flint 1988). In
domestic species large and small luteal cells do not occupy distinct
compartments within the gland (Conley et al 1995).
Human
In women, structure of the corpus luteum is different to that seen in domestic
species. The theca lutein layer lies at the periphery of the gland, with clumps of
these small dense cells lying between the larger paler granulosa lutein cells and
the fibrous sfroma of the gland (Clement et al 1987). The theca lutein cells
invaginate the granulosa lutein cell layer along fibrous trabeculae which give
the gland a characteristic wheel and spoke appearance (Sasano et al 1989;
Corner 1956).
1.1.3 Luteal function
Production of steroid and protein hormones by the corpus luteum changes
throughout the lifespan of the gland. Particular functional changes occur in the
presence or absence of hCG in conception and non-conception cycles
respectively.
Progesterone production
In the follicular phase of the cycle development of follicles is principally
controlled by FSH. Under the influence of FSH, LH receptor expression is
induced in the dominant follicle (Richards 1980; Segaloff et al 1990), and
progesterone production in the human commences approximately 12 hours
prior to the LH surge (Hoff et al 1983). Progesterone secretion increases as the
corpus luteum forms, and reaches a maximum between 5 and 10 days after
ovulation. If conception has not occurred, production of progesterone then falls
from days 11-14 of the luteal phase facilitating menstruation and the start of a
new ovarian cycle. If pregnancy has occurred, hCG secreted from the
implanting fetoplacental unit permits continued secretion of the increasing
amounts of luteal progesterone until the placenta assumes this function later in
pregnancy (Strott et al 1969; Caldwell et al 1980; lllingworth et al 1990).
The human corpus luteum secretes up to 25mg of progesterone per day
(Strauss et al 1981). Although the corpus luteum has the capability to
synthesise cholesterol de novo (Talavera and Menon 1989), the majority of
cholesterol is delivered to the gland by the circulation in the form of LDL (low
density lipoproteins) and FIDL (high density lipoproteins) (Tandeski et al 1996).
The rate determining step for the conversion of cholesterol to progesterone is
the transport of cholesterol into the mitochondria of the steroidogenic cells (Flail
1985; Behrman and Aten 1991). Recent advances have demonstrated that
steroid acute regulatory protein (STAR) acts as a critical transport protein for
cholesterol at this step, allowing for subsequent conversion of pregnenelone to
progesterone by P450 enzymes on the inner mitochondrial membrane (Stocco
and Clark 1996).
Oestrogen production
Corpora lutea of the majority of domestic species are not capable of oestrogen
secretion (Conley et al 1995). In contrast, primate corpora lutea synthesise
oestrogens in addition to progesterones (Ohara et al 1987; Hild-Petito et al
1989).
In primates, oestrogen may be an important regulator of ovarian function during
the luteal phase. Luteal oestrogen feeds back at the level of the pituitary and
hypothalamus to inhibit FSH and GnRH secretion and thus suppress follicle
development during the luteal phase (Yamaji et al 1972; Bhattycharya et al
1972). In domestic species which do not produce luteal oestrogens FSH levels
are not suppressed and follicles develop in waves throughout the luteal phase.
Inhibin production
In addition to steroid hormones, the corpus luteum also secretes protein
hormones, principally inhibin and relaxin (Baird and Smith 1993). The primate
corpus luteum produces inhibin A which may act through negative pituitary
feedback in non-primate species (Campbell et al 1992), however experimental
evidence is lacking for the speculation that a similar negative feedback loop
exists in primates (Fraser and Lunn 1993; Fraser and Tsonis 1994). In parallel
with progesterone, inhibin A is a marker of luteal function in women, and levels
of inhibin decline after withdrawal of gonadotrophin support in the mid luteal
phase (Fraser et al 1989) or enucleation of the corpus luteum in women and
primates (Basset et al 1990; I Hi ng worth et al 1991). The corpus luteum also
produces high levels of inhibin a- subunit which is thought to be biologically
inactive. Its function may be paracrine but this has yet to be elucidated.
1.1.4 Changes associated with luteinisation
Follicles of primates and domestic species exhibit a clear demarcation between
theca and granulosa layers. The layers are separated by a basement
membrane and while the theca cell layer has a blood supply the granulosa
lutein cell layer is avascular and is thought to obtain nutrients and oxygen by
diffusion (Bassett 1943; McClure et al 1994). Morphological studies have
demonstrated that following the LH surge the basement membrane between
the granulosa and theca cells breaks down (McKay et al 1961) and the
steroidogenic cells increase in size and number (Gillim et al 1969).
Haemorrhage of blood into the central cavity and between the parenchymal
cells of the gland is observed in the 48 hours following ovulation (Corner 1956).
The central cavity later fills with fibrin and undergoes organisation (McKay et al
1961).
As these changes occur the vascular supply grows from the thecal cell
compartment to supply the previously avascular granulosa cell compartment.
Within 4 days of ovulation a dense vascular network has formed to supply the
previously avascular granulosa cells with a rich vascular supply (Corner 1956;
McClure et al 1994).
1.1.5 Changes associated with luteolysis
In a non-fertile cycle the corpus luteum undergoes both functional and structural
regression. Endocrine activity diminishes at the end of the luteal phase (Baird
1984; Butcher et al 1974). The structure of the corpus luteum also starts to
break down, diminishing in size and becoming less well demarcated from
surrounding ovarian tissue (Deikman et al 1978; Braden et al 1988). During the
next ovarian cycle the corpus luteum becomes small and pale and is known as
a corpus albicans.
Functional luteal regression.
From day 10 of the luteal phase onwards, the output of the human corpus
luteum falls, in terms of progesterone, oestrogens and inhibin (Butcher et al
1974; Baird 1984 ). The fall in progesterone allows endometrial shedding and
menstruation to occur while the corresponding the fall in oestrogen and inhibin
permits upregulation of FSH and follicle recruitment (Knobil 1974).
Structural luteal regression.
This term refers to changes in the morphology of the corpus luteum at the end
of its lifespan. The corpus luteum undergoes a reduction in size, and there is
evidence to suggest that immune cell infiltration of the gland (Brannstrom and
Norman 1993), vascular changes (Reynolds et al 1992; Redmer and Reynolds
1996) and cell death (Tilly 1996) may have major roles in this process.
Control of luteal lifespan
The control of luteal lifespan is subject to considerable species variation
(Auletta and Flint 1988; Bazer 1992). If conception has not occurred in
domestic species uterine PGF2« reaches the corpus luteum through a local
counter current mechanism and induces regression (McCracken et al 1981).
After hysterectomy in such animals the corpus luteum persists for a period of
time equivalent to the gestational period of the species (Florton and Poyser
1976). In the absence of a uterine luteolytic signal, it appears that there is an
inherent non-uterine regulator of luteal lifespan. It is possible that intra-ovarian
factors induce luteal regression in these circumstances.
in women hysterectomy does not affect ovarian cyciicty (Beling et al 1970), and
luteal regression is not induced by a uterine factor. The precise mediators of
luteal regression in women are not well understood.
1.1.6 Changes associated with luteal rescue and pregnancy
In the presence of a conceptus, luteal function and structure are maintained,
and increasing quantities of progesterone are secreted. The size and the
vascular supply of the corpus luteum increase in line with these changes in
hormone production (Atkinson et al 1975; Baber et al 1988; Salim et al 1994).
(a) Non-primates
In domestic animals such as sheep and cattle, trophoblast interferons exert a
paracrine antiluteolytic effect on the endometrium to inhibit production of
luteolytic pulses of PGF2a (Sharp et al 1989; Fincher et al 1986; Bazer 1992).
In the absence of this luteolytic signal, luteal structure and function are
maintained to support the developing intrauterine pregnancy. No definitive
luteotropic factors have been described in domestic species.
(b) Human
Although there is no uterine luteolytic signal in the human, the uterus secretes a
luteotropic factor, hCG, from the time of implantation (Flearn et al 1991). This
glycoprotein binds to the common LH receptor to bring about the maintenance
of function and structure which is termed luteal rescue. Progesterone and
inhibin production are thus maintained in early pregnancy (Tovanabutra et al
1993). hCG is essential for luteal rescue as immunisation against this hormone
results in decreased progesterone production and termination of pregnancy
(Talwar 1997). The post-receptor mechanisms by which hCG brings about
increased size and steroid production by the corpus luteum are unknown.
1.1.7 Clinical relevance
Progesterone secreted by the hCG rescued corpus luteum is essential for the
maintenance of early pregnancy. Disruption of luteal function in early
pregnancy, before or after implantation, is a possible means of post-coital
contraception, monthly menses-inducing contraception or early termination of
pregnancy.
Defects in luteal formation, rescue or secretion may lead to early miscarriage, a
problem which affects 12 to 15% of pregnancies in the UK (Simpson 1996).
However, no prospective randomised controlled trials exist to document
therapeutic efficacy of supplementation of spontaneous pregnancy with
exogenous progesterone (Carson 1996).
Improved understanding of the control of luteal function may provide a basis for
the development of new forms of fertility control or interventions for early
pregnancy loss.
1.1.8 Analogies with tumour tissue.
The corpus luteum has many features in common with neoplasms including an
exceptionally quick growth (Zheng et al 1994), high blood flow (Bruce and Moor
1976), and high rates of proliferation (Jablonka-Shariff et al 1993) and
angiogenesis (Reynolds et al 1992). in addition, in parallel with neoplastic
tissue, growth of the corpus luteum may be regulated by programmed cell
death (Tilly 1996), angiogenic factors (Koos 1989; Redmer and Reynolds 1996)
and immune cells (Brannstrom and Norman 1993). There may be parallels
between the physiological mechanisms important for formation and rescue of
the corpus luteum and those involved in the growth of malignant tissue.
The low rates of malignant transformation in the corpus luteum (Jeffcoate 1987)
may be related to the observation that steroidogenic luteal cells are fully
differentiated. However, paracrine factors such as reducing agents or
angiogenesis inhibitors which may prevent cell growth in the corpus luteum may
have therapeutic implications for malignancies in other tissues.
1.2 Lack of knowledge of factors which determine luteal lifespan.
1.2.1 LH/hCG and LH receptor
Luteal function is dependent on LH secretion from the pituitary (Smith 1930;
Vande-Weil et al 1970; Hutchison and Zeleznik 1984). LH is a dimeric
glycoprotein hormone secreted in pulses into the bloodstream which binds to G-
protein coupled receptors on steroidogenic cells in the corpus luteum. Through
these receptors it induces cAMP and progesterone synthesis (Dennefors et al
1982; McFarland et al 1989; Eyster et al 1985).
If LH secretion is blocked or removed then the corpus luteum undergoes
regressive changes and progesterone secretion falls (Behrman et al 1971; Mais
et al 1986). These changes are reversed by replacement of LH (Fraser et al
1985). In vitro, progesterone production from luteinised granulosa cells
increases following LH stimulation (LeMaire et al 1968; Stouffer et al 1977).
However secretion of LH remains at relatively low levels throughout the luteal
phase and does not parallel changes in progesterone secretion (Behrman et al
1993). Spontaneous luteal regression in primates is not associated with a
decrease in LH secretion (Behrman 1993). Neither is luteal regression due to
changes in the pulsatile nature of LH secretion as decreased pulse frequency
does not alter luteal function in primates (Zeleznik 1991). Other factors which
interrupt luteal responsiveness to LH may thus be important.
Changes in the binding characteristics of the LH receptor have been implicated
in luteal regression. LH binding studies in the corpus luteum show a fall in line
with progesterone secretion during functional luteolysis but expression of the
LH receptor is not down regulated at this time (Lee et al 1977; McNeilly et al
1980; Ravindranath et al 1992a). Changes in cAMP production have been
observed while LH receptor number is constant (Rojas et al 1989), and this may
represent uncoupling of the LH receptor at the end of the luteal phase.
During early pregnancy hCG is essential for luteal rescue. LH binding and
receptor expression remain unchanged at the time of luteal rescue (Duncan et
al 1996d), however continued LH secretion is insufficient to prevent luteolysis
(Behrman et al 1993). hCG therefore acts with the receptor in a manner distinct
to that of LH. This is supported by the observation that the presence of
persistently high levels of hCG are not associated with the down regulation of
LH receptors which is observed with continuous secretion of LH (Caldwell et al
1980; Stouffer et al 1987).
1.2.2 Other putative factors in luteal regression
Factors implicated in luteal regression in non-primate species have been
investigated in primate corpora lutea. In particular, the role of PGF2« in
luteolysis in primates has been widely studied and is controversial because of a
number of conflicting results.
Prostaglandins, including PGF2a, are synthesised in the primate corpus luteum
(Challis et al 1976; Swanston et al 1977; Patwarden and Lanthier 1985;
Houmard and Ottobre 1989). Although one group have found increased levels
of PGF2a in regressing corpora lutea (Patwardhan and Lanthier 1985), other
workers have not confirmed this finding (Michael et al 1994). Receptors for
PGF2a are also present in primate corpus luteum (Powell et al 1975; Tanaka et
al 1983), but it is not known if their abundance or distribution changes with
luteal function.
In vitro, PGF2q reduces LH stimulated cAMP secretion in mid luteal phase
tissue (Dennefors et al 1982; Khan-Dawood et al 1989), but in vivo studies give
discordant results (Wentz and Jones 1973; Korda et al 1975; Bennegard et al
1991). Infusion of PGF2a into the corpus luteum of the rhesus monkey is
luteolytic (Auletta et al 1984; Hearn and Webley 1987), but systemic,
intravaginal or intraovarian administration in women causes only a transient
reduction in progesterone synthesis (Wentz and Jones 1973; Karim and Hillier
1979; Wilks 1980). The luteal phase is only slightly prolonged if prostaglandin
synthesis is blocked by administration of ibuprofen, a cyclooxygenase inhibitor
(Auletta and Flint 1988).
No studies have examined PGF2a or its receptor during luteal rescue in early
pregnancy in women.
Oestrogens have also been implicated as physiological luteolysins in women.
When given systemically or locally oestrogens are associated with a fall in
progesterone production (Auletta et al 1972; Gore et al 1973; Karsch and
Sutton 1976). This may however be due to inhibition of LH secretion due to
feedback at the pituitary. If oestrogens are administered to primates by
intraluteal pump at a rate that does not alter circulating levels of oestrogens or
gonadotrophins luteal regression results (Auletta et al 1985). Flowever further
studies imply that this may not be the physiological process responsible for
luteal regression as blocking studies using anti-oestrogens (Westphal and
Resko 1982) or aromatase inhibitors (Ellinwood and Resko 1983) have failed to
inhibit spontaneous luteal regression.
Other factors such as oxytocin (Tan et al 1982; Maas et al 1992) and free
radicals (Margolin et al 1990; Endo et al 1993) have been implicated in luteal
regression and maintenance in women. Despite a large body of literature
luteolytic mechanisms in primates are poorly understood.
1.2.3 Interactions between luteal cell types may bring about changes in
luteal function.
Previous studies have focused mainly on changes involving steroidogenic luteal
cells, but the corpus luteum contains a greater number of non-steroidogenic
than steroidogenic cells (Lei et al 1991; Zheng et al 1993). It is possible that the
various cell types in the gland may interact in a number of ways to bring about
changes in luteal function and structure.
1.3 Proliferation in the corpus luteum
1.3.1 Luteal growth
As the progesterone output of the corpus luteum increases in both domestic
species and primates during luteal formation and rescue, luteal weight also
increases. Similarly, as progesterone secretion falls at the end of the cycle,
luteal weight is reduced (Zheng et al 1994; Christenson and Stouffer 1996).
These changes may be due to increases in the number or the size of the cells
which constitute the corpus luteum.
1.3.2 Luteal cell proliferation
Changes in cell proliferation at different stages of luteal function have been
studied using both morphological and immunohistochemical techniques.
Morphological studies detect small numbers of mitotic figures in steroidogenic
cells during the early luteal phase, but no mitoses are seen at later stages.
(Corner 1956; Meyer and Bruce 1980; O'Shea et al 1980;1986). However,
identification of morphological features of mitosis may not be the most sensitive
or specific method of detecting proliferation.
Cells undergoing replication may only be identified by morphological features
during the relatively short-lived M phase of the cell cycle, and pyknotic or
fragmented nuclei may cause confusion in identifying mitotic bodies (Meyer
1982; Sasaki et al 1987). Furthermore, numbers of mitotic bodies may be
altered by fixation techniques which can distort mitotic figures (Graem and
Helweg-Larsen 1979; Cross et al 1990). These limitations have lead to
utilisation of immunohistochemical proliferation markers in the study of luteal
cell proliferation.
In corpora lutea of domestic species cells identified using immunohistochemical
proliferation markers are most abundant during formation of the gland shortly
after ovulation. With luteal maturation, proliferation rates decrease and remain
at a constant level until the end of the cycle (Jablonka-Shariff et al 1993; Zheng
et al 1994; Nicosia et al 1995). The majority of proliferating cells in the corpus
luteum are of endothelial phenotype (Meyer and McGeachie 1988; Jablonka-
Shariff et al 1993; Zheng et al 1994).
These morphological and immunohistochemical studies suggest that changes
in progesterone production are associated with changing rates of luteal
proliferation and angiogenesis in non-primates. At the outset of the work
described in this thesis there was little information describing rates of
proliferation in primate corpora lutea, throughout the luteal phase or during
luteal rescue.
1.4 Luteal vasculature
1.4.1 Importance of luteal vasculature
The rapid growth and regression of the corpus luteum may be accompanied by
equally rapid changes in its vascular bed and high rates of proliferation have
been found in the endothelial cells of corpora lutea of domestic species (Meyer
and McGeachie 1988; Jablonka-Shariff et al 1993; Zheng et al 1994). The
corpus luteum is a highly vascular structure, with the highest blood supply of
any tissue (Ellinwood et al 1978; Reynolds 1986; Reynolds et al 1992; 1994)
and receives over 90% of the blood flow to the ovary (Bruce and Moor 1976;
Bruce et al 1984). In the mature corpus luteum each steroidogenic cell is in
direct contact with at least one endothelial cell (Dharmarajan et al 1985; Zheng
et al 1993). The vascular bed of the corpus luteum is in the form of sinusoidal
vessels which are not surrounded by smooth muscle. These are thought to offer
low resistance to blood flow which may be dependant on arterial pressure and
the extent of the vascular bed (Wiltbank et al 1990).
The vascular supply of the corpus luteum is essential for the delivery of
gonadotrophic hormones, steroidogenic substrates and oxygen to steroidogenic
cells (Koos 1989). Changes in the vascular supply of the corpus luteum may
therefore influence its function.
1.4.2 Luteal blood flow in non-primates.
Serum progesterone is positively correlated to the rate of luteal blood flow in the
ovary containing luteal tissue in non-primates (Nett et al 1976; Niswender et al
1976). A decrease in luteal blood flow is associated with ovine luteal
regression, and blood flow increases in early pregnancy in rats (Bruce and
Moor 1976; Bruce et al 1984). Blood flow to the rabbit corpus luteum is however
unchanged by hCG treatment (Wiltbank et al 1989).
Care must be taken when extrapolating results of blood flow studies in domestic
animals to primates, as PGF2a, the uterine luteolysin, may cause constriction of
luteal vessels at regression (Pharris and Wyngarden 1969).
Ovarian blood flow in domestic species varies with changes in luteal function.
Conversely, decreased vascularisation is associated with inadequate luteal
phase in these species (Niswender and Nett 1988).
1.4.3 Clinical studies of luteal blood flow.
A number of studies have used Doppler ultrasound to examine luteal blood flow
throughout the luteal phase in women. These studies have shown that luteal
blood flow increases shortly after ovulation to a maximum level at days 7-9 after
the LH peak (Bourne et al 1996; Alcazar et al 1996; Salim et al 1994). Blood
flow to the corpus luteum then declines from luteal days 10 or 11 in a non fertile
cycle. There is a positive correlation between systolic blood flow velocity, luteal
volume and serum progesterone in women, and luteal low blood flow is
associated with luteal phase defect in women (Glock et al 1995). No Doppler
ultrasound studies describe changes in blood flow over the first 14 days of
normal pregnancy in women.
Clinical studies also provide evidence that luteal blood flow may be related to
functional status in early pregnancy. These investigations have shown that a
high resistive Doppler index (i.e. a low flow) is associated with missed abortion,
incomplete and threatened miscarriage, and luteal phase defect (Deichert et al
1996; Salim et al 1994).
1.4.4 Angiogenesis
Morphological studies have shown that during development of the corpus
luteum an intricate vascular network forms in a short space of time. The
angiogenic process begins with formation of a new microcirculatory bed
composed of arterioles, capillaries and venules. The sprouting of new blood
vessels requires that endothelial cells degrade their surrounding extra cellular
matrix, migrate towards an angiogenic stimulus and proliferate. Blood vessel
formation is completed by formation of capillary lumina and differentiation of
newly formed capillaries into arterioles and venules (Reynolds et al 1992).
1.5 Angiogenic factors
1.5.1 Luteal angiogenic factors
In domestic species the corpus luteum is characterised by a high rate of
endothelial proliferation (Reynolds et al 1992), and blood vessel formation may
regulate luteal function (Reynolds et al 1992;1994). The rate of vasculogenesis
varies throughout the luteal phase, and is influenced by changes in LH
secretion (Redmer et al 1988). There is controversy over expression of LH
receptor by luteal endothelial cells (Ghinea et al 1994; Duncan et al 1996d) and
paracrine factors may be involved in regulation of luteal angiogenesis. Luteal
tissues, tissue extracts and conditioned media (Jakob et al 1977; Grazul-Bilska
et al 1992; Redmer et al 1985) have been shown to stimulate angiogenesis in
vivo and in vitro bioassays.
1.5.2 Angiogenic potential of the corpus luteum.
Prenant noted that the corpus luteum was a highly vascular structure in 1898,
but the angiogenic potential of the corpus luteum was not demonstrated until
79 years later. Studies implanting samples of luteal tissue into chick
chorioallantoic membrane (an in vivo assay of angiogenic potential) showed
that bovine luteal tissue could induce neovascularisaton (Jakob et al 1977,
Redmer et al 1988). Previously this effect had been observed with implanted
malignant tumour tissue but not with normal adult tissues (Folkman and Cotran
1976). Angiogenic activity was subsequently observed using luteal tissue from
rabbits (Gospodarowicz and Thakral 1978), pigs (Heder et al 1979; Ricke et al
1995) and rats (Koos and Le Maire 1983), and endothelial migration was
induced by ovine, bovine and porcine luteal extracts (Redmer et al 1988;
Grazul- Bilska et al 1991; Doraiswamy et al 1995a;b). Subsequent studies
demonstrated that the ovine corpus luteum induced proliferation and migration
of endothelial cells at different stages of luteal function and in pregnancy
(Grazul- Bilska et al 1992;1995).
Attempts to identify secreted angiogenic mediators in luteal extracts isolated a
factor which bound strongly to heparin, was heat labile and was neutralised by
antibodies directed against bFGF (basic fibroblast growth factor) (Grazul- Bilska
et al 1993). A further secreted angiogenic factor was neutralised by antibodies
directed against VEGF (vascular endothelial growth factor) (Doraiswamy et al
1995a). bFGF and VEGF may be principal local regulators of angiogenesis in
the ovary (Koos 1989; Redmer and Reynolds 1996).
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1.5.3 Basic fibroblast growth factor
bFGF (also known as FGF-2) is one of the most potently angiogenic members
of a family of nine mitogens known as fibroblast growth factors (Folkman and
Klagsburn 1987). bFGF was first isolated from pituitary (Gospodarowicz et al
1985) and is synthesised by macrophages, parenchymal cells of tumours and
endothelial cells (Basilico and Moscatelli 1992; Kuwabara et al 1995). Four
different molecular weight forms of bFGF have been identified; bFGF18, 22,
22.5 and 24 (Florkiewicz and Somer 1989), arising from differential transcription
and post-translation modification of a single gene product (Bugler et al 1991;
Florkiewicz et al 1991; Quarto et al 1991; Renko et al 1991). The 18kDa form is
predominantly located in the cytoplasm, while the larger forms localise to the
nucleus (Renko et al 1991). bFGF lacks a signal sequence (Abraham et al
1986) and the mechanism for its release into the extracellular milieu is unknown
(Rifkin and Moscatelli 1989).
bFGF stimulates endothelial cell growth , migration and protease synthesis in
vitro (Moscatelli et al 1988;1986; Mignatti et al 1989) and promotes formation of
differentiated capillary tubes in vivo (Montesano et al 1986). bFGF is widely
distributed throughout the body and is expressed in tissues where angiogenesis
occurs at low as well as high rates (Gosparadowicz et al 1987; Folkman and
Klagsburn 1987; Koos 1989; Basilico and Moscatelli 1992). This implies that
bFGF may maintain the vasculature of certain tissues while inducing vascular
growth in others.
This growth factor is not selective for endothelial cells and is mitogenic for a
range of cells of mesodermal and neuroectodermal origin (Bikfalvi et al 1997).
bFGF has been detected in bovine, ovine and porcine luteal tissues and
conditioned media (Grazul-Bilska et al 1992; Zheng et al 1993; Schams et al
1994; Doraiswamy et al 1995b; Ricke et al 1995), and has been
immunolocalised to steroidogenic cells and connective tissue tracts in ovine
and bovine corpora lutea (Grazul- Bilska et al 1992; Zheng et al 1993; Schams
et al 1994). Expression of bFGF in the bovine ovary increases after formation
of the corpus luteum to peak in the mid luteal phase and decline thereafter
(Zheng et al 1993). In contrast, no variation in bFGF production has been
observed at different stages in the ovine corpus luteum (Grazul- Bilska et al
1992). bFGF distribution or expression has not been investigated in the primate
corpus luteum.
bFGF acts through a number of structurally related tyrosine kinase linked
receptors (Erickson et al 1991; Zhu et al 1991) which are predominantly
localised in endothelial cells in adult tissues (Bikfalvi 1997). FGF receptor-1 has
been demonstrated in the rat in luteal endothelial cells at all stages and on
steroidogenic cells prior to functional regression (Doraiswamy et al 1995b).
FGF receptor-2 is present in steroidogenic cells throughout the lifespan of the
gland (Redmer and Reynolds 1996).
1.5.4. Vascular endothelial growth factor
VEGF (also known as vascular permeability factor) is a 40kDa heparin binding
glycoprotein dimer (Senger et al 1987; Connolly et al 1989b; Senger et al 1990;
Ferrara and Henzel 1989; Gospodarowicz et al 1989). Four different isoforms
arise from alternative splicing; VEGF 121, 165, 189 and 206, of which VEGF
165 is predominantly expressed (Tischer et al 1991; Park et al 1993). This
growth factor has specific mitogenic effects on endothelial cells and acts as an
angiogenic factor in vivo (Ferrara and Henzel 1989; Leung et al 1989), but also
increases vascular permeability (Connolly et al 1989a;b; Senger et al 1993).
Increased vascular permeability aids angiogenesis by causing leakage of
plasma proteins and deposition of an extra-vascular fibrin gel which is a
substrate for endothelial cell growth (Dvorak 1986; Dvorak et al 1987).
VEGF expression is upregulated by hypoxia in a similar manner to
erythropoetin (Schweiki et al 1992; Minchenko et al 1994; Levy et al 1995;
Shima et al 1995), and VEGF and bFGF promote angiogenesis in a synergistic
manner (Pepper et al 1992; Stavri et al 1995).
Distribution of VEGF mRNA is temporally and spatially related to proliferation of
blood vessels in the rat (Phillips et al 1990), mouse (Schweiki et al 1993) and
primate ovary (Ravindranath et al 1992b) and in the rat uterus (Cullinan-Bove
and Koos 1993), suggesting that VEGF is a mediator of the cyclical growth of
blood vessels that occurs in the female reproductive tract (Ferrara and Davis-
Smith 1997). VEGF expression is also detectable around microvessels in areas
where endothelial cells are normally quiescent such as kidney glomerulus,
pituitary, heart, lung and brain (Brown et al 1992; Ferrara and Flenzel 1989;
Monacci et al 1993). It is possible that VEGF may be required not only to
induce active vascular proliferation but also to maintain the differentiated state
of blood vessels.
VEGF binds with high affinity to two tyrosine kinase linked receptors, fit and kdr
(Shibuya et al 1990; Terman et al 1991 ;1992; de Vries et al 1992). Ligand
autoradiography and in situ hybridisation studies in rat demonstrate that VEGF
binding sites are largely restricted to vascular endothelium (Jakeman et al
1992; 1993; Peters et al 1993; Quinn et al 1993). VEGF and its receptors are
vital for normal development. Inactivation of the VEGF gene in mice results in
embryonic lethality in heterozygotes at days 11-12 of pregnancy (Carmeliet et
al 1996; Ferrara et al 1996). This is due to gene dosage effect as VEGF mRNA
can be detected at lower levels in heterozygous animals.
Mice homozygous for a targeted mutation in flt-1 die in utero between days 8.5
and 9.5 (Fong et al 1995). Inactivation of a murine form of kdr is associated
with lethality at the same stage (Shalaby et al 1995).
At the outset of the work described in this thesis VEGF had been detected in
cultures of luteinised human granulosa cells (Ravindranath et al 1992b) but had
not been localised in the corpus luteum of any species.
VEGF expression may be influenced by the hypothalamic-pituitary-ovarian
axis. VEGF expression increases in cultured bovine luteal cells in response to
LH stimulation (Garrido et al 1993), and cultured human luteal cells upregulate
VEGF production after hCG stimulation (Neulen et al 1995). In vivo studies
reveal that continued treatment of monkeys with GnRFI antagonist results in
down regulation of luteal VEGF expression (Ravindranath et al 1992b). No
studies have examined VEGF production in early pregnancy.
1.5.5 Other potential angiogenic factors
Although bFGF and VEGF are the best characterised angiogenic factors
produced by the corpus luteum, other factors which affect blood vessel
formation are produced by the gland.
The angiogenic activity of the ovine corpus luteum can be partly neutralised by
antibodies directed against aFGF (acidic fibroblast growth factor), also known
as FGF-1 (Grazul-Bilska et al 1993). This factor is a member of the same
cytokine family as bFGF, but is a less potent endothelial mitogen (Folkman and
Klagsburn 1987; Zagzag 1995). aFGF has been localised in large and small
bovine luteal cells, although it is present at lower levels than bFGF (Zheng et al
1993).
Cytokines produced from immune and steroidogenic cell compartments also
exert mitogenic effects on endothelial cells. In addition to functioning as
chemotactic factors for immune cells, MCP-1 (monocyte chemoattractant
protein-1) and IL-8 (interleukin 8) have angiogenic properties (Kelly et al 1997;
Koch et al 1992; Nakashima et al 1995). These cytokines have been localised
to steroidogenic cells in rat and pig corpora lutea (MCP-1) (Flosang et al 1994;
Townson et al 1995) and luteinised granulosa cells in women (IL-8) (Arici et al
1986). MCP-1 and IL-8 may also be produced by immune cells in the corpus
luteum (Arici et al 1996; Yoshimura et al 1987).
Macrophages are the most prevalent type of immune cell in the human corpus
luteum (Brannstrom and Norman 1993; Brannstrom et al 1994a; Best et al
1996) and products of luteal macrophages may have angiogenic properties
(Brannstrom and Norman 1993). TGF-p (transforming growth factor beta), TNF-
a (tumour necrosis factor alpha), interleukin 1 and interleukin 6 are present in
the corpus luteum and may be indirectly angiogenic (Roby and Terranova
1989; Motro et al 1990; Ji et al 1991; Vassali 1992; Simon et al 1994).
Although these factors promote angiogenesis in vivo (Koos 1989), in vitro
studies demonstrate no effect on endothelial cell proliferation, migration or
protease synthesis (Brannstrom and Norman 1993).
In tumour tissues angiogenesis is regulated by an interplay between angiogenic
and antiangiogenic factors from tumour cells and the circulation (Folkman 1995;
Flolmgren et al 1995). No study has yet addressed whether antiangiogenic
factors are present in the corpus luteum. If present, these agents may interact
with angiogenic mediators to regulate vessel formation in the corpus luteum.
1.5.6 Non secreted factors
Non-secreted and structural factors may be important in the regulation of luteal
angiogenesis.
The matrix of the corpus luteum plays a role in the formation of new blood
vessels (Duncan et al 1996a;b;c). Degradation of the extracellular matrix is
essential for angiogenesis. VEGF induces production of proteases by
endothelial cells, but steroidogenic luteal cells also produce matrix
metalloproteinases (Duncan et al 1996a) which break down the extra cellular
matrix. The major protein product of steroidogenic luteal cells is TIMP (tissue
inhibitor of metalloproteinases) (Duncan et al 1996b), which inhibits breakdown
of the matrix. These high levels of TIMP may be important for the control of
angiogenesis in the corpus luteum.
Blood vessel growth is dependent on proliferation of endothelial cells, but
changes in the rate of death of endothelial cells will also affect angiogenic rates.
Different types of cell death have been described in endothelial cells in ovine
and human corpora lutea (O'Shea et al 1977; Modlich et al 1996; Fraser et al
1995). Endothelial cell death may be influenced by local production of growth
hormones from steroidogenic or immune cells. Changing rates of cell death
may represent another regulatory point in the control of the luteal vasculature.
In addition to the extent of the luteal vasculature, the blood flow to the corpus
luteum may also be regulated by vascular tone. Vasoconstriction may result in
reduced luteal flow during luteal regression, and uterine PGF2a may reduce
luteal flow by this mechanism in domestic species. In primates, local factors
such as nitric oxide production, hypoxia and prostaglandins may bring about
changes in vascular tone and luteal flow.
1.5.7 Antiangiogenic agents
Antiangiogenic agents are being evaluated for use as cancer treatments (Toi
1995). Administration of these agents in a mouse model of lung carcinoma
causes a significant reduction in tumour size. Tumour shrinkage is not mediated
by a decrease in proliferation, but by a significant increase in the rate of cell
death in the tumour (Flolmgren et al 1995). This may be directly due to a
decreased blood supply, or to more indirect factors such as decreased local
production of growth factors.
In a similar way changing rates of angiogenesis in the corpus luteum may be
associated with changing rates of cell death during luteal regression and
maintenance.
1.6 Cell death in the corpus luteum
1.6.1 Luteal growth and cell death
A high rate of cellular proliferation, particularly in endothelial cells, is
characteristic of the corpus luteum throughout its functional lifespan.
Proliferation in the gland is tightly regulated and the corpus luteum is rarely the
site of malignant transformation. Cell death plays an opposite but
complementary role to mitosis in regulation of cell populations in other tissues
(Wyllie 1992). Cell death may balance proliferation in the corpus luteum and
changes in the rate of cell death in endothelial and steroidogenic cells may
allow growth in early pregnancy or regression at the end of the cycle.
1.6.2 Cell death in the corpus luteum
Early descriptions of luteal morphology include features that today are
recognised as characteristic of cell death. Two main morphological forms of cell
death have been identified in the corpus luteum; (1) apoptosis and (2) necrosis
(O' Shea et al 1977; Sawyer et al 1990; Fraser et al 1995)
Necrosis involves varying numbers of adjacent cells and usually follows a
pathological insult to the tissue, while apoptosis is concerned with the deletion
of single cells in the midst of healthy tissue (Kerr et al 1972; Ueda and Shah
1994). Apoptosis is observed as a normal part of developmental and
physiological processes (Kerr et al 1972; Ueda and Shah 1994), and is also
involved in regression of malignant tumours (Wyllie 1992; Holmgren et al 1995;
Thompson 1995).
Increasing morphological and biochemical evidence suggests that apoptosis
may be important in control of luteal structure and function.
1.6.3 Apoptosis- historical perspective
The first morphological features of selective cell death in any tissue were
described in the ovary by William Flemming who in 1885 noted that the
epithelial lining of regressing follicles contained cells with fragmenting nuclei.
Flemming called this process chromatolysis, referring to the fragmented
nucleus which usually disappeared. A further description of the same
morphological changes in lactating mammary gland was published the following
year (Nissen 1886). A paper published in 1914 by Graper stated that
"chromatolysis must exist in all organs in which cells must be eliminated"
implying that this type of cell death was physiological. The concept of cell
suicide was first proposed in the 1950s when DeDuve speculated that cells
might be killed from within (quoted in Manjo and Joris 1995). The term
apoptosis was first used to describe these changes in 1972. In ancient Greek
the word apoptosis describes leaves falling one by one from trees in autumn
(Kerr et al 1972).
1.6.4 Apoptosis and programmed cell death
The phenomenon known as programmed cell death refers to situations where
cells are programmed to die at a fixed time (Bowen 1993; Manjo and Joris
1995). Such cells usually but not always die by apoptosis, for example
apoptosis is responsible for the death of cells between digits in the embryonic
hand and foot (Saunders and Fallon 1967), but is not observed during the
massive programmed cell death observed during formation of the nervous
system (Server and Mobley 1991). Similarly, extrinsic factors such as ionising
radiation can induce apoptosis in cells where it has not been pre-programmed
(Lowe et al 1993a;b). Programmed cell death refers to the set of commands
within a cell that will signal it is time for that cell to die while apoptosis refers to
the type of death that cell then undergoes.
General characteristics of apoptosis are well established and include
morphological and biochemical characteristics. Cells undergoing apoptosis
shrink and become denser. The chromatin becomes pyknotic and is packed
into smooth masses applied against the nuclear membrane creating semi¬
circular shapes. The nucleus of the cell may then break up. The cell emits
processes which may break off and form apoptotic bodies, which are
phagocytosed by tissue macrophages and neighbouring cells (Kerr et al 1972;
Wyllie et al 1980; Manjo and Joris 1995). In contrast to necrosis, there is little or
no swelling of intracellular organelles, and apoptotic cells do not attract
lymphocytes and macrophages. However when apoptosis occurs on a large
scale as seen in the embryo, an influx of phagocytes is involved with disposal of
apoptotic bodies (Duvall et al 1985; Savill et al 1990). The process of apoptosis,
from the appearance of the first morphological changes to the phagocytosis of
cellular remnants, is extremely rapid, with a duration of between 15 minutes
and 1 hour (Manjo and Joris 1995). This may explain scanty morphological
evidence of apoptosis in some tissues where this form of cell death is thought
to occur at high rates.
Biochemically, apoptosis is associated with a characteristic pattern of DNA
degradation. DNA is wrapped around protein cores known as histones, with one
histone holding 180-200 base pairs of DNA (Bortner et al 1995). During
apoptosis, the DNA is cleaved between histones, so the segments of DNA
remaining are multiples of 180-200 base pairs long. Resolution on a gel gives
rise to the typical laddering pattern associated with apoptotic cell death (Wyllie
1980). In apoptotic cells DNA is thought to be degraded by an endogenous
calcium and magnesium dependant endonuclease which bears many
similarities to DNAase 1 (Peitsch et al 1994).
This contrasts with the pattern of DNA degradation associated with necrosis
where DNA can be cleaved at any point. When resolved on a gel DNA from
necrotic tissue results in a smear of different sized DNA fragments (Wyllie
1993).
DNA degradation in apoptosing cells may also be examined by 3' end labelling
where a biochemical tag is attached to broken ends of degraded DNA (Gavrieli
et al 1992; Ansari et al 1993). This method has been used to identify apoptotic
cells in tissue sections. However this method is not specific for apoptosis as
DNA fragmentation also occurs at a late stage during necrotic cell death .
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1.6.5 Apoptosis in reproductive tissue
Apoptosis has been observed in reproductive tissues and may be regulated by
hormonal factors.
In the endometrium apoptosis is observed in the glandular epithelium and
increases in frequency as the secretory phase of the menstrual cycle
progresses, peaking during menstruation (Tabidzadeh et al 1994; Gu et al
1994). Progesterone and TNFa may be involved in cyclic regulation of
endometrial apoptosis (Koh et al 1995). There is also evidence that apoptosis
is involved in decidual regression during blastocyst implantation (Ackali et al
1996).
The first historical description of morphological features of apoptosis was
concerned with ovarian follicles (Flemming 1885). Apoptosis is now thought to
be responsible for perinatal germ cell loss (Coucouvanis et al 1993; Pesce and
de Felicici 1994) and follicular atresia (Tilly 1993; Ratts et al 1995; Tilly and
Ratts 1996). Gonadotrophins are effective inhibitors of apoptosis occurring in
granulosa cells of follicles deprived of trophic support in vitro (Chun et al 1994;
Tilly and Tilly 1995). Progesterone has also been implicated in the control of
follicular apoptosis (Luciano et al 1994).
Other examples of hormonally regulated apoptosis in the reproductive system
include the inhibition of apoptosis by testosterone in the prostate gland
(Kyprianou et al 1990) and by oestrogen in the breast (Wang and Phang 1995).
Apoptosis occurs in a cyclical manner in the female reproductive system and
can be influenced by hormonal factors. Apoptosis may be important in
regulating luteal lifespan. Endocrine, paracrine or autocrine factors may play a
role in the control of apoptosis in the corpus luteum.
1.6.6 Apoptosis in the corpus luteum
There is growing evidence to support the hypothesis that apoptosis may occur
during luteal regression. The rate of cell death in the gland may be fundamental
for the control of its lifespan, and the constant length of the luteal phase
suggests that death may be pre-programmed into these cells.
Morphological features consistent with apoptosis have been observed in
corpora lutea of domestic species, marmoset monkeys and women (Corner
1956; Sawyer et al 1990; Young et al 1996). DNA cleavage characteristic of
apoptosis was first described in luteinised rat granulosa cells in vitro (Zeleznik
et al 1989) and was followed by the demonstration of oligonucleosome
formation in regressing cow corpora lutea (Jeungel et al 1993; Rueda et al
1995). Subsequent investigations have shown that DNA laddering also occurs
in regressing corpora lutea from other domestic species, marmoset monkeys
and women (Shikone et al 1996; Young et al 1996).
Luteal apoptosis has also been examined by 3'end labelling studies. This
method has revealed that positive cells in cow, sheep, monkey and human are
more numerous during luteal regression (Zheng et al 1994; Rueda et al 1995;
Funayama et al 1996; Shikone et al 1996; Young et al 1996). Studies in women
have observed a low incidence of 3' end labelled cells in early pregnancy
suggesting that down regulation of apoptosis may be important for maintaining
the structure and function of the gland in early pregnancy. eCG has been
shown to reduce apoptotic death in cultured granulosa cells (Tilly et al 1995),
and it is possible that hCG could also lower apoptotic rates in the corpus luteum
in women.
The majority of apoptotic cells in the corpus luteum, as assessed by
morphology and 3'end labelling, are of steroidogenic origin. Apoptotic
endothelial cells have also been described in morphological studies (O'Shea et
al 1977; Fraser et al 1995). Changing rates of apoptosis in both of these cell
compartments may be implicated in luteal regression and maintenance.
1.6.7 Regulation of apoptosis by internal factors
The role of hormones in regulating apoptosis has already been discussed, but
apoptosis may also influenced by local factors such as growth factor production
(Lynch et al 1986; Araki et al 1990; Duke and Cohen 1990; Williams et al 1990)
and trophic stimulation from neighbouring cells (Raff 1992). The fate of the cell
may also be controlled by internal factors such as proto-oncogene expression.
Many proto-oncogenes which have varying effects on the fate of a cell have
been identified. The precise mechanisms by which these proto-oncogenes
influence the fate of the cell are unknown, but they have well conserved actions
throughout phylogeny of species (Wyllie 1992; Hengartner and Horvitz 1994).
Although cell death may be induced solely by proto-oncogene expression
external factors may interact with proto-oncogenes to induce apoptosis. A high
turnover state may be induced in a cell by expression of proto-oncogenes such
as c-myc (Evan et al 1992; Wyllie 1992; 1993; Harrington et al 1994). In this
situation an excess of local growth factors may lead to proliferation, where
absence of growth factors may lead to apoptosis (Wyllie 1992; Fandini et al
1992). In the corpus luteum, this implies that apoptosis may be regulated by
proto-oncogene expression within steroidogenic and endothelial cells but also
by hormone and growth factor availability.
1.6.8 Bcl-2 and apoptosis
The bcl-2 proto-oncogene (B cell lymphoma/leukaemia -2) was identified at the
breakpoint site of the t(14; 18) translocation that is associated with follicular
lymphoma and its expression prevents cell death induced by a wide range of
apoptotic stimuli (Tsujimoto and Croce 1986). Immunocytochemical localisation
of bcl-2 within cells has revealed its association with mitochondrial membranes,
endoplasmic reticulum and the nuclear envelope (Hockenbery et al 1990;
Monaghan et al 1992; Riparbelli et al 1995). The precise mechanism of action
of bcl-2 is not known but it can function in cells which lack a nucleus and also in
those which lack mitochondrial DNA (Jacobson et al 1993;1994). It has been
proposed that bcl-2 may act as an antioxidant or free radical scavenger to
protect cells from the damaging effects of reactive oxygen species (Kane et al
1993; Hockenbery et al 1993). Bcl-2 expression has been shown to be
topographically restricted to tissue characterised by high rates of programmed
cell death (Hockenbery et al 1991).
1.6.9 Bcl-2 in reproductive tissues
Bcl-2 is particularly interesting as its expression prevents cell death induced by
a wide range of apoptotic stimuli and has been implicated in the selection of
ovarian follicles and regulation of apoptosis in the endometrium (Gompel et al
1994; Tilly et al 1995; Tilly 1996).
Bcl-2 is expressed in glandular epithelium and spiral arteries in the
endometrium and its expression is maximal at the end of the proliferative phase
(Otsuki et al 1994). With declining bcl-2 levels in the secretory phase apoptosis
appears in the endometrial glands. The cyclicity of bcl-2 expression suggests
that it may be regulated by hormonal factors. This is supported by the
observation that variations in expression of bcl-2 occur after treatment with
oestrogen and progesterone in endometrium and breast. However the promoter
region sequence of bcl-2 contains no recognised steroid regulatory elements
(Akcali et al 1996).
Bcl-2 is expressed at lower levels in decidua of women with failing pregnancies
when compared to those with normal pregnancies, and may be involved in
survival of syncytiotrophoblast during placentation (Lea et al 1997). Bcl-2
expression has been examined in rat follicles. Bcl-2 is expressed in granulosa
cells but levels of expression do not change during selection for dominance or
atresia (Tilly et al 1995).
Ablation of functional bcl-2 through targeted disruption of the gene in mice
(gene knockout) leads to significantly fewer oocytes and primordial follicles in
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the postnatal ovary, but granulosa cell apoptosis is not affected (Ratts et al
1995).
1.6.10 Bcl-2 and bax
In recent years it has become apparent that bcl-2 is one member of a family of
structurally similar proto-oncogenes which act to promote or suppress
apoptosis (Nunez and Clarke 1994). The homology among the bcl-2 related
proteins is concentrated in two regions, termed BH1 and BH2 (Yin et al 1994).
In addition, proteins of the bcl-2 family contain a stretch of hydrophobic amino
acids at their C terminal which may be important for membrane insertion
(Nguyen et al 1993). At the outset of the work described in this thesis, only bcl-
2 and bax had been described.
Bax protein was identified by immunoprecipitation of bcl-2. Bax is a 21kDa
protein with 21% homology to bcl-2. Bax forms heterodimers with bcl-2, and
induces apoptosis (Oltvai et al 1993). It is unclear which of bcl-2 or bax is the
effector protein or which is the blocking protein. It appears that the rate of
apoptosis in a tissue is more closely related to the bcl-2 /bax ratio than to
absolute levels of either of the proto-oncogenes. Bax is distributed in a wider
range of tissues than bcl-2 (Krajewski et al 1994a), implying that it may interact
with other bcl-2 family members or that bax may have alternative functions not
involved with apoptosis. Interactions between bax and bcl-2 are thought to be
important in ovarian follicle selection. Although bcl-2 levels remain constant
throughout follicular development, bax levels are higher in follicles destined for
atresia than those which become dominant (Tilly et al 1995). In other tissues
such as endometrium bax levels remain unchanged while bcl-2 levels decrease
to induce apoptosis. (McLaren et al 1997) The bcl-2/ bax ratio, rather than the
absolute level of either is the most important indicator of the fate of a cell.
The pattern and distribution of bcl-2 and bax expression throughout the lifespan
of the corpus luteum and in early pregnancy are not known for any species.
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1.6.11 Overview
Apoptosis may be a controller of luteal growth and lifespan. Programmed cell
death is controlled by the expression of a number of proto-oncogenes. Patterns
of proto-oncogene expression in the corpus luteum have not been
characterised. Endocrine, paracrine and autocrine factors may influence the
expression of apoptotic proto-oncogenes within the corpus luteum.
1.7 The immune system and luteal function
1.7.1 Immune cell interactions in the corpus luteum
Immune cells are present in the corpus luteum and have previously been
implicated in structural luteal regression. However these cells may be important
not only during regression, but throughout the lifespan of the gland.
A role is emerging for immune cells in the control of ovulation (Brannstrom and
Norman 1993) and this may extend to a regulatory role in the corpus luteum.
Suppression of the immune system can disrupt ovarian function and may alter
luteal lifespan (Wang et al 1993; Alila and Hansel 1984)
Interactions between cells of the immune and reproductive systems may
influence steroidogenic output (Halme et al 1985; Emi et al 1991; Yan et al
1993) and blood vessel growth (Koch et al 1992; Vassali et al 1992), and may
regulate the balance between cell death and proliferation in the corpus luteum
(Fukuoka et al 1989; Wang et al 1991; Redmer et al 1996). It is possible that
changes in immune cell number, distribution or cytokine production may
influence the function of the corpus luteum during luteal regression and
maintenance. Leukocytes may also be important for formation and continuing
function of the mature corpus luteum.
1.7.2 Immune regulation of luteal function.
Cells of the immune system may regulate luteal function. Suppression of
immune function using glucocorticoids in the rat prolongs luteal function in
hysterectomised animals, although immunosuppression does not counter
PGF2« induced luteal regression (Wang et al 1992). The effects of
immunosuppression on luteal function in women are unknown.
Conversely, in vitro studies have demonstrated that peripheral blood leukocytes
or their secretory products can increase progesterone production from
luteinised human granulosa cells (Emi et al 1991). Hence the immune system
may be capable of both stimulating and inhibiting luteal function under different
circumstances.
Macrophages (Gillim at al 1969; Wang et al 1992), neutrophils (Brannstrom et
al 1994a), and lymphocytes (Best et al 1996) have been identified in human
corpora lutea and studies indicate that numbers of macrophages increase in
spontaneous luteolysis in the human (Lei et al 1991; Brannstrom et al 1994a)
while numbers of neutrophils increase during PGF2a mediated luteal regression
in the rat (Brannstrom et al 1993; 1994b). Free radical production by neutrophils
may have a luteolytic effect as neutrophils incubated with luteal cells from rat
decreased LH stimulated progesterone production but this effect was blocked
by SOD and catalase(Peperell et al 1992). In addition, production of
intracellular ROS by cultured luteal cells increased in the presence of activated
neutrophils. No increase in neutrophil number is observed during spontaneous
luteolysis in women (Brannstrom et al 1994a).
Recent studies by Duncan and colleagues (Duncan et al 1998) have examined
macrophage distribution during luteal maintenance and regression in women.
Macrophages were numerous in the late luteal phase and at this time the
majority of macrophages were situated at the junction of the theca and
granulosa lutein cells. Macrophage numbers fell significantly following hCG
treatment. It is not known whether other leukocyte subsets vary with changing
luteal function.
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1.7.3 Secretory products of leukocytes
Immune cells can affect luteal function in a number of ways. As well as their
role in cell death and phagocytosis, cells of the immune system may break
down the extracellular matrix of the gland or affect steroidogenesis by free
radical production (Behrman et al 1993).
Cytokines are an important group of factors secreted by leukocytes which can
cause changes in the surrounding cells. These factors may act directly on
granulosa and theca lutein cells to influence steroidogenesis (Sjorgen et al
1991; Fairchild et al 1992; Fukouka et al 1992), or act indirectly to affect the
luteal vasculature, act as growth factors or alter rates of programmed cell death
in the corpus luteum (Yan et al 1993; Tilly 1996).
Tumour necrosis factor alpha (TNFa) is secreted by macrophages and T
lymphocytes and has been identified in corpora lutea of domestic animals and
humans (Roby et al 1990). In vitro experiments in the cow suggest that this
cytokine can suppress progesterone biosynthesis (Fairchild et al 1992).
Progesterone biosynthesis by hCG stimulated luteinised granulosa cells is also
decreased in women in vitro by IL-2, which is secreted by T cells (Wang et al
1991). In contrast IL-1, secreted by neutrophils and macrophages has been
shown to increase basal and hCG stimulated progesterone synthesis in
luteinised human granulosa cells (Sjorgen et al 1991).
1.7.4 Steroidogenic cells may produce chemotactic factors
Macrophages are most prevalent during luteal regression and are less
abundant in the human corpus luteum after hCG stimulation (Duncan et al
1998). As luteal macrophages do not express the LH receptor (Duncan et al
1996d), the change in macrophage numbers associated with hCG treatment
may be mediated by a steroidogenic cell product.
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MCP-1 (monocyte chemoattractant protein-1) has been localised to
steroidogenic luteal cells in the rat (Hosang et al 1994). Rising levels of this
peptide are associated with a macrophage influx during functional luteolysis in
the rat (Townson et al 1995;1996). MCP-1 production is inhibited by
physiological levels of progesterone (Kelly et al 1997) and it is possible that the
decline in progesterone associated with functional luteal regression allows
upregulation of MCP-1 production. This may in turn trigger an influx of
macrophages necessary for structural regression of the corpus luteum. Patterns
of MCP-1 production in the human corpus luteum are unknown.
Similarly, IL-8 is chemotactic and activating for neutrophils in vivo and in vitro
(Baggiolini et al 1989) and is also angiogenic (Koch et al 1992). IL-8 expression
has been identified in cultured human granulosa lutein cells (Arici et al 1996).
The pattern of IL-8 expression with changing luteal function has not been
investigated, but steroidogenic cell IL-8 secretion may allow neutrophils to enter
the gland at times where proteolytic digestion is required for tissue remodelling.
1.7.5 Overview
The cells and secreted factors of immune, steroidogenic and endothelial
compartments interact in complex ways in the corpus luteum. Immune cells are
present throughout the luteal phase and numbers may rise in luteal regression.
This increase may be mediated by chemotactic factors from steroidogenic cells.
With the potential to affect the function and growth of endothelial and
steroidogenic cells the immune system may be an important regulator of luteal
function throughout the lifespan of the gland.
1.8 Summary
Luteal cells may interact directly or by means of secreted products. Such
interactions may change the rate of cell growth or death in the gland, and may
alter its steroidogenic potential, its ts cellular composition.
Post LH receptor mechanisms regulating luteal function and lifespan are likely
to involve complex interactions between the different cell types of the gland.
This thesis sets out to dissect physiological processes which may be involved in
luteal regression and maintenance in women, and examines how the different
cell types of the gland may influence these processes.
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CHAPTER 2
TISSUE COLLECTION AND CHARACTERISATION
2.1 Introduction
Studies on cellular interactions in the human corpus luteum were undertaken on
human tissue. Ovarian biopsies were obtained from premenopausal women
undergoing hysterectomy for benign conditions. To simulate early pregnancy,
and allow comparisons between luteal maintenance and regression hCG
(Profasi, Serono, Randolph, MA, USA) was administered to maintain the
lifespan of the corpus luteum. Ethical approval for hCG treatment and removal
of luteal tissue was sought and obtained from the reproductive subdivision of
Lothian regional ethics committee.
2.2 Recruitment of donors: Controls.
Corpora lutea were obtained from premenopausal women who were expected
from dates of their last menstrual period to be in the luteal phase of the
menstrual cycle at the time of their planned hysterectomy.
2.2.1 Inclusion and exclusion criteria
Inclusion criteria for the study were as follows:
a) Age 18-45 years
b) Awaiting elective abdominal hysterectomy.
c) Regular menstrual cycles.
Exclusion criteria were as follows:
a) Suspicion of malignant disease
b) Hormonal medication
c) Concurrent disease
d) History of infertility
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2.2.2. Recruitment protocol
Suitable patients were identified from gynaecology waiting list clinical notes. A
patient information letter (figure 2.1) was sent to all patients identified as
potentially suitable. This letter briefly outlined the purpose of our studies and
gave a telephone number which interested women could contact. On contacting
our group requirements of the study were explained in detail and suitability to
participate was determined. In particular, the date of the last menstrual period
was ascertained. If the date of planned surgery was due to fall in the luteal
phase of the cycle, daily urine collection was commenced for serial LH tracking
allowing the day of the LH surge to be determined. A detailed medical history
was obtained and the subject signed a standard consent form. Venous blood
was sampled for estimation of serum progesterone on the day of surgery.
2.3 Recruitment of donors: hCG treatment
In addition to the control group, a group of 14 women who were scheduled to
have surgery during functional luteal regression received hCG treatment in
order to simulate the endocrine effects of early pregnancy.
2.3.1 Treatment protocol
Patients were initially recruited by letter as detailed for control subjects. The
patient information sheet for the treatment group is shown in figure 2.2. In 8
subjects who were scheduled for surgery 24 and 30 days after their last
menstrual period, urine samples collected daily for LH tracking were analysed
between 2 and 5 days after the expected day of ovulation. The day of the
urinary LH peak was taken as day 0, with subsequent serum progesterone
estimations confirming ovulation. Treatment with hCG (Profasi, Serono) to
mimic the endocrine effects of early pregnancy was commenced on day 7 of
the luteal phase. The hCG was administered by intramuscular injection for
between 5 and 8 consecutive days in incremental doses beginning with 1251U
per day then doubling daily to a maximum of 16,000IU. Administration of hCG
over more than 8 days was precluded by pain associated with the injection of
increasing volumes of hormone. Venous blood was collected on alternate
days during hCG administration as well on the day of surgery and plasma was
stored at -20°C for subsequent radioimmunoassay for progesterone. The
serum concentrations of hCG, progesterone and inhibin produced by this
regime have been shown previously to be similar to those seen in normal
pregnancy (lllingworth et al 1990; lllingworth et al 1996). hCG treatment lasted
for a mean of 7.5 days (range 5-8 days). Serum progesterone levels rose
significantly (p<0.05) from a mean of 34.5 nmol/l prior to treatment to a mean of
43.9 nmol/l on the day of operation, confirming luteal rescue in each case
(figure 2.3).
2.3.2 Inclusion and exclusion criteria
Inclusion criteria for hCG treatment were as follows:-
a) Age 18-45 years
b) Awaiting elective abdominal hysterectomy
c) Regular menstrual cycles
d) Due to have surgery 24-30 days after last menstrual period
Exclusion criteria for hCG treatment were as follows:-
a) Suspicion of malignant disease
b) Hormonal medication
c) Concurrent disease
d) History of infertility
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2.4 Characterisation of luteal age and function
In order to correlate changes in the corpus luteum with the functional status of
the gland the time (in days) since ovulation was determined for each luteal
biopsy.
2.4.1 Menstrual history
A detailed menstrual history was taken prior to tissue retrieval. Subjects had
regular menstrual cycles, allowing the age of the corpus luteum to be
estimated.
2.4.2 Urinary LH tracking
All subjects collected daily urine samples in the cycle leading up to their
operation. Approximately 5mL of urine per day was collected and stored in a
domestic freezer until collection on admission to hospital. Serial urine samples
were subjected to radioimmunoassay for LH by Mrs F Pitt of the MRC
Reproductive Biology Unit. Urinary LH levels were expressed as LH/creatinine
ratios to allow for changes in urine concentration. In all cases where a corpus
luteum was obtained an LH surge was easily identified, allowing accurate luteal
dating (Djahanbakhch et al 1981).
2.43. Serum progesterone determination
Venous blood was taken on the day of surgery from control group subjects to
allow assessment of the functional state of the corpus luteum. Venous blood
samples were collected on alternate days during hCG administration as well as
on the day of surgery. Plasma was stored at -20°C for subsequent
radioimmunoassay for progesterone by Mrs F Pitt, MRC Reproductive Biology
Unit.
2.4.4 Endometrial morphology
Endometrial samples retrieved from luteal donors at hysterectomy were fixed in
4% paraformaldehyde for 24 hours, processed and mounted in paraffin blocks.
Haematoxylin and eosin stained 5p,m sections cut from these blocks were
dated according to the criteria of Li et al (1988) by Dr WC Duncan, MRC
Reproductive Biology Unit. This gave further validation of luteal age at retrieval.
2.4.5 Assignment to early, mid, late or rescued group.
After the date of ovulation and functional state of the corpora lutea had been
determined, control subjects were grouped according to luteal age as follows:
early luteal, 1-4 days since ovulation (n=11); mid luteal, 5-9 days since
ovulation (n=11); late luteal, 10-14 days since ovulation (n=15).
hCG treated subjects (n=14) were identified as rescued corpora lutea.
2.5 Collection and storage of tissue
2.5.1 Removal at laparotomy
At laparotomy the corpus luteum was identified and enucleated from the ovary.
This was characteristically accompanied by only minimal blood loss. One or two
stitches were required to repair the defect in the ovary in approximately 10% of
cases. In cases where oopherectomy was planned, the corpus luteum was
enucleated from the ovary prior to ligation of the ovarian vessels. Immediately
after removal the corpus luteum was cut into radial sections which were
processed for either fixing or freezing.
After removal of the uterus at laparotomy a longitudinal incision was made with
a scalpel from the fundus to the cervix until the uterine cavity was exposed.
Endometrial samples were retrieved from the uterine cavity with forceps and
fixed in 4% paraformaldehyde for subsequent dating studies.
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2.5.2 Frozen tissue
Radial sections of corpus luteum were frozen using two different methods.
Sections were placed in labelled cryotubes and frozen immediately in liquid
nitrogen for subsequent storage at -70°C. A further section of corpus luteum
was coated in OCT tissue medium, frozen on a slurry of dry ice and isopentane
and subsequently stored at -70°C for frozen section use.
2.5.3 Fixed tissue
Radial sections of corpus luteum and endometrial biopsies were fixed for 24
hours in 4% paraformaldehyde in 0.1 M phosphate buffered saline pH7.4. After
tissue processing, sections were embedded in paraffin blocks and stored at
room temperature for subsequent use.
2.6 Analysis of tissue obtained
2.6.1 Number of donors per year
Numbers of luteal biopsies obtained declined from 28 in the first year of the
study (1993) to only 3 in the last full year of the study (1996) (figure 2.3). A
number of factors accounted for this fall. Firstly, the number of patients
identified from clinical notes as suitable for luteal donation fell from 206 in 1993
to 100 in 1996. The proportion of replies to recruitment letters did not vary
significantly over the course of the study.
Subjects who replied to the recruitment letter but were found to be unsuitable
after detailed discussion and urinary LH tracking rose from 39% in 1993 to
70% in 1996. Subjects who were expected to be in the follicular phase of their
cycle on the day of surgery accounted for the majority of these cases (65%).
Other reasons for unsuitability included hormonal treatment which had not been
previously identified from clinical notes (22%), laparoscopically assisted vaginal
hysterectomy (8%) and high risk status (2%). This may reflect increasing use of
hormonal treatments for menstrual symptoms or an increasing trend towards
laparoscopically assisted vaginal hysterectomies (LAVH). LAVH is a procedure
which is unsuitable for luteal retrieval as the corpus luteum will have been
avascular for approximately 45 minutes before delivery of the pelvic organs
through the vagina.
The proportion of suitable subjects who had an identifiable corpus luteum at
laparotomy did not vary significantly over the study period (range 39-74%).
2.6.2 Demographic details
Demographic details for luteal donors were as follows:
a) Mean age of donors was 40 years (range 29-42 years). Mean age did not
change significantly over the years of the study. Mean donor age was 40 years
for each of the early, mid, late and rescued groups.
This study includes a large proportion of women who are of older reproductive
age (median age 40 years). However all luteal donors demonstrated midcycle
urinary LH peaks and all subjects had ovulatory progesterone concentrations
apart from the late luteal group where the low concentration would be
anticipated. In addition, Klein et al, 1996 has shown that while older women
have marked differences in early phase FSH and inhibin B concentrations
compared with younger women, there is no difference in the function of either
the dominant follicle or the corpus luteum.
b)The commonest indication for hysterectomy in luteal donors was menorrhagia
(54%), followed by fibroids (22%) and endometriosis (14%). Other indications
for hysterectomy are shown in figure 2.4.
c) The majority of luteal donors (73%) underwent a total abdominal
hysterectomy with ovarian conservation. Total abdominal hysterectomy and
bilateral salpingo-oophorectomy was performed in 17% of donors, while 7% of
donors underwent total hysterectomy with a unilateral oophorectomy. Subtotal
hysterectomy with ovarian conservation was performed in 2% of donors. A
further 2% underwent subtotal hysterectomy with bilateral salpingo-
oophorectomy.
2.6.3 Assessment of luteal function.
Venous blood was obtained for serum progesterone determination on the day
of operation for the control group, and every 48 hours as well as on the day of
operation during hCG treatment. Mean serum progesterone levels rose from
21.8ng/mL (confidence limits 16.4 - 27.2nmol/L) in the early luteal phase to
34.5ng/ml_ (confidence limits 26.8 - 42.2nmol/L) in the mid luteal phase. Levels
fell significantly to 18.7nmol/L (confidence limits 14.1 - 23.3nmol/L) in the late
luteal phase, p<0.05). hCG treatment was associated with significant increase
in serum progesterone to a mean of 43.9nmol/L (confidence limits 39.0- 48.8
nmol/L, p<0.05) in the rescued group (figure 2.5).
Figure 2.1
Patient information sheet (control group)
THE MECHANISM OF PREGNANCY RECOGNITION IN WOMEN
PATIENT INFORMATION SHEET
CONTROL GROUP
Research into the establishment of early pregnancy in women.
What is the research about?
The establishment of early pregnancy is a very important process in women
and problems such as infertility and early miscarriage are unfortunately very
common. It is known that a woman's body will recognise pregnancy as a result
of a hormone called hCG which is produced by the early embryo. This hormone
hCG stimulates the ovary leading to all the other changes of pregnancy.
However, we still do not understand the critical processes by which the ovary
recognises this hCG and thus acts to maintain the pregnancy. This research is
therefore intended to improve our understanding of early pregnancy.
What will be involved?
Each month at the time of a period, the ovary forms new cells which produce
hormone and then release an egg at the time of ovulation. If pregnancy does
not occur, these cells continue to produce hormone for 14 days before they die
at the time of the next period. In this research we propose to remove these cells
(which will die anyway) from the ovary at the time of your operation. This will
extend the operation by approximately five minutes but will not add anything to
the discomfort normally experienced at such an operation. In addition there will
be no effect on your future hormone production.
In addition you will be asked to collect urine samples during the days leading up
to your operation in order that we can measure your normal hormone
production.
Your participation or otherwise in this research will not in anyway affect the
treatment you will receive at the Royal Infirmary and you will be free to withdraw
at any time.
Further information is available from Dr Faye Rodger, Clinical Research Fellow,
MRC Reproductive Biology Unit.
Figure 2.2
Patient information sheet (hCG treatment group)
THE MECHANISM OF PREGNANCY RECOGNITION IN WOMEN
PATIENT INFORMATION SHEET
hCG TREATMENT GROUP
Research into the establishment of early pregnancy in women.
What is the research about?
The establishment of early pregnancy is a very important process in women
and problems such as infertility and early miscarriage are unfortunately very
common. It is known that a woman's body will recognise pregnancy as a result
of a hormone called hCG which is produced by the early embryo. This hormone
hCG stimulates the ovary leading to all the other changes of pregnancy.
However, we still do not understand the critical processes by which the ovary
recognises this hCG and thus acts to maintain the pregnancy. This research is
therefore intended to improve our understanding of early pregnancy.
What will be involved?
Each month at the time of a period, the ovary forms new cells which produce
hormone and then release an egg at the time of ovulation. If pregnancy does
not occur, these cells continue to produce hormone for 14 days before they die
at the time of the next period. In this research we propose to remove these cells
(which will die anyway) from the ovary at the time of your operation. This will
extend the operation by approximately five minutes but will not add anything to
the discomfort normally experienced at such an operation. In addition there will
be no effect on your future hormone production.
In order to investigate how the ovary responds to hCG, you will be given small
amounts of hCG by daily injection for up to eight days. This is a naturally
occurring female hormone which is in regular use in infertility treatment at much
larger doses with no significant side-effects. In particular, there will be no
pregnancy symptoms at this very low dosage and no long term effects on your
body.
Finally, blood samples will be required on alternate days in the days leading up
to your operation and you will be asked to collect daily urine samples in order
that we can measure your normal hormone production.
Your participation or otherwise in this research is entirely voluntary and will not
in any way affect the treatment that you will receive at the Royal Infirmary and
you will be free to withdraw at any time. We will not be able to make any
payments to volunteers for helping us with this research but will meet the cost
of any expenses incurred by volunteers.
Figure 2.3
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ENDOTHELIAL CELL PROLIFERATION IN THE HUMAN CORPUS LUTEUM
3.1 Introduction
3.1.1 Luteal vasculature
The contribution of local vasculature to regulation of luteal function in women is
unclear but evidence from other species suggests that control of endothelial cell
function may be important. The corpus luteum has the highest blood supply per
unit weight of any organ in the body (Bruce and Moor 1976; Wiltbank et al
1988). Approximately 50% of cells in the mature rat corpus luteum are
endothelial cells resulting in the majority of steroidogenic cells being in contact
with at least one capillary (Dharmarajan et al 1985; Reynolds et al 1992; Zheng
et al 1993). Luteolysis in the sheep is associated with a rapid diminution in the
luteal blood flow which falls at a much greater rate than tissue weight implying
that luteal regression is preceded by changes in the vasculature (Bruce and
Moor 1976). Although the prostaglandins which effect ovine luteolysis exert an
action on blood vessel tone, it is possible that declining numbers of blood
vessels may also be involved.
3.1.2 Clinical studies
There is indirect evidence to link vascular supply with luteal function in women.
Ultrasound measurements of blood flow in women have demonstrated a
positive correlation between successful pregnancy and low vascular resistance
thus suggesting that high luteal blood flow may be required for early pregnancy
support (Baber et al 1988).
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3.1.3 Angiogenesis and luteal function
Blood vessel growth may parallel the functional state of the corpus luteum.
Angiogenesis has been examined in the non-pregnant human corpus luteum
using immunostaining for endothelial and proliferation markers (McClure et al
1994). Although no significant changes were noted earlier in the luteal phase, a
fall in endothelial cell proliferation was noted in the last five days of the cycle.
Further studies examining proliferation in the human corpus luteum used P450
aromatase immunostaining as a marker of luteal function. In corpora lutea no
longer expressing this enzyme, cell proliferation had fallen to a low level
(Funayama et al 1996). Thus, luteal regression may be associated with
declining levels of proliferation. It is not known whether endothelial cell
proliferation changes during luteal rescue in early pregnancy.
3.1.4 Aims of chapter
The aim of this chapter was to investigate whether changes in function at
different stages of the lifespan of the human corpus luteum are associated with
either the number or the rate of proliferation of endothelial cells. In particular the
effects of treatment with hCG at doses similar to those seen in early pregnancy
were examined.
These questions were addressed by identifying endothelial cells using
immunostaining with a monoclonal antibody directed against von Willebrand
factor (an intrinsic clotting cascade protein specific for cells of endothelial
lineage), and Ki67, which specifically binds to proliferating cells.
3.2 Materials and methods
3.2.1 Immunohistochemistry for von Willebrand factor
Sections (5[xim) were cut onto Tespa (Sigma, Poole, UK) coated slides, air-
dried at 56°C, dewaxed in xylene then rehydrated in 100%, 95%, and 70%
ethanol. Sections were then incubated in 0.1% trypsin (Sigma) pH 7.4 at 37°C
for 40 minutes. Endogenous peroxidase activity was inhibited using 0.3%
hydrogen peroxide in methanol for 30 minutes and the sections were
preabsorbed for 20 minutes with normal rabbit serum (SAPU, Carluke, UK).
In order to identify endothelial cells, a monoclonal antibody raised against
human von Willebrand factor protein (vWF) was used (Dako, High Wycombe,
UK). The primary antibody was applied at 1:50 dilution (0.134 mg/mL IgG
concentration). For control sections, 0.134 mg/mL of mouse IgG (Vector,
Peterborough, UK) was used in place of primary antibody. After incubation for
20 hours at 4°C, the secondary antibody, biotinylated rabbit anti-mouse
(Vector) was applied for 45 minutes. Colouring was obtained with
diaminobenzidine by means of an avidin-biotin reaction with horseradish
peroxidase (Vector).
3.2.2 Immunohistochemistry for Ki67
In order to identify proliferating cells, a monoclonal antibody to the nuclear non¬
histone antigen, Ki67, was used on serial sections. These serial sections were
prepared in a similar way to those above, but were exposed to two 10 minute
cycles and one 5 minute cycle of microwave irradiation at 700w, in citrate buffer
0.01 M, pH 6.0 (Shi et al 1993) in place of the trypsin digestion step. Monoclonal
human Ki67 antibody (Novocastra, Peterborough, UK) was applied at a 1:50
dilution and sections were incubated at 37°C for 2 hours. Detection of the
primary antibody was carried out in the same manner as for vWF. Sections of
human tonsil immunostained for Ki67 in the same way as luteal tissue were
included in all immunohistochemistry procedures to provide positive and
negative tissue controls; in every experiment, the germinal centres of the tonsil
exhibited positive immunostaining while the periphery exhibited no
immunostaining.
3.2.3 Immunohistochemistry for 30 hydroxysteroid dehydrogenase
In order to determine the nature of non-endothelial cells staining positively for
Ki67, dual staining for Ki67 and 30 hydroxysteroid dehydrogenase (30HSD)
was undertaken to identify the steroid-producing cells. Sections prepared as
above for Ki67 immunohistochemistry were then exposed to polyclonal 30HSD
antibody raised in rabbit (gift of Prof Van Luu-The, CHUL Research Centre,
Quebec) at a dilution of 1:1000 for 20 hours at 4°C. Negative control sections
were exposed to normal rabbit serum at the same dilution (Dako). Antigen was
detected by means of an avidin/biotin/alkaline phosphatase reaction with Vector
Red (Vector).
3.2.4. Data analysis
The total number of cells exhibiting immunostaining for vWF was counted in
four high power fields (x200) from opposite quadrants of the glandular
component of the section. This figure was expressed as number of vWF cells
per high power field. The serial sections which had been stained for Ki67 were
similarly analysed. The total number of cells exhibiting immunostaining for Ki67
in the four fields were counted and expressed as number of Ki67 positive cells
per high power field. In order to quantify the nature of non-endothelial cells
expressing Ki67 antigen, steroidogenic cells were identified with 30HSD
antibody. The total number of cells co-localising 30HSD and Ki67 was counted
in four high power fields from opposite quadrants of the glandular component of
the section and expressed as a percentage of the total number of Ki67 positive
cells in that field.
In all cases the observer was unaware of the nature of the section being
examined. Preliminary investigations showed that increasing the number of
fields above four did not increase statistical accuracy of the estimations (For
early luteal phase sections increasing number of fields examined to eight
resulted in mean endothelial cell count per high power field of 120, confidence
intervals 99-141; and mean Ki67 positive cell count of 249, confidence intervals
190-308).
Differences in the number of cells expressing antigen per high power field were
investigated by one-way analysis of variance using stage of the luteal phase as
a between subject (corpus luteum) variable with Fischers PLSD test. The
numbers of antigen-expressing cells in late and rescued corpora lutea were
also compared in the same manner.
3.3 Results
3.3.1 Endothelial cells
Endothelial cells were identified by positive immunostaining for vWF in all
corpora lutea examined. A similar pattern was seen in each section, with larger
arterioles and venules lying in the fibrous capsule of the gland, and endothelial
cells of small capillaries lying between the steroidogenic cells (figure 3.1).
The number of endothelial cells present in the corpus luteum exhibited
significant variation relative to the stage of the luteal phase (figure 2a; p<0.05).
The number of cells present in the early luteal phase (117; confidence intervals
97-137 cells per high power field) was significantly lower than in the mid luteal
phase (276; confidence intervals 256-296 cells per high power field; p<0.05)
and late luteal phase (254; confidence intervals 236-272 cells per high power
field; p<0.05). No significant difference was observed between the number of
endothelial cells in the late corpus luteum and that in the hCG stimulated
corpus luteum (238; confidence intervals 216-260 cells per high power field;
p=0.17)
3.3.2 Proliferating cells
Ki67 immunostaining was also observed in all sections examined. The majority
of cells exhibiting positive immunostaining were endothelial cells (figure 3.1).
The number of proliferating cells of all types present in the corpus luteum, as
judged by positive Ki67 staining, exhibited significant variation relative to the
stage of the luteal phase (p<0.05). The number present in the early luteal
phase (248, confidence intervals 168-328 cells per high power field) was
significantly higher than that in the mid-luteal phase (43; confidence intervals
29-57 cells per high power field; p<0.05) and late luteal phase (53, confidence
intervals 40-66 cells per high power field; p<0.05). No significant difference was
observed between the total number of proliferating cells in the late corpus
luteum and that in the hCG stimulated corpus luteum (78; confidence intervals
55-101 cells per high power field; p=0.26).
3.3.3 Proliferating endothelial cells
The number of endothelial cells present which were positive for Ki67 also
exhibited significant variation relative to the stage of the luteal phase (figure
2b). The number present in the early luteal phase (120, confidence intervals 98-
142 cells per high power field) was significantly higher than in the mid-luteal
phase (24, confidence intervals 10-38 cells per high power field; p<0.05), and
late luteal phase (30, confidence intervals 21-39: p<0.05). No significant
difference was observed between the number of proliferating endothelial cells in
the late corpus luteum and that in the hCG stimulated corpus luteum (47,
confidence intervals 33-61 cells per high power field; p=0.49).
3.3.4 Proliferating non-endotheliai cells
The total number of proliferating cells of non-endothelial origin followed a
similar pattern, exhibiting significant variation relative to the stage of the luteal
phase (figure 2c; p<0.05). The number present in the early luteal phase (128,
confidence intervals 70-166) was significantly higher than that in the midluteal
phase (19, confidence intervals 15-23; p<0.05) and late luteal phase (22,
confidence intervals 19-25; p<0.05). No significant difference was observed
between the number of proliferating non-endothelial cells in the late corpus
luteum and that in the hCG stimulated corpus luteum (31, confidence intervals
21-41 cells per high power field; p=0.38).
3.3.5 Proliferating steroidogenic cells
Proliferating steroidogenic cells were rare, making up less than 5% of total
proliferating cells (figure 3.3). There was no significant variation in total number




This study demonstrates that cell proliferation follows the mid-cycle LH surge
and continues throughout the luteal phase, but simulated early pregnancy in
women is not associated with a further increase. Proliferating cells were present
at all stages of the luteal phase and during luteal rescue. The largest sub-group
of proliferating cells were endothelial. Dual immunostaining of 3|3HSD and Ki67
demonstrated that very few of the proliferating non-endothelial cells were
steroidogenic. Morphological studies have demonstrated that during formation
of the corpus luteum endothelial cells grow inwards from the stroma to supply
the steroidogenic cells of the gland (Zheng et al 1993). After this initial phase of
growth endothelial cell proliferation has been shown to continue at a lower
level, falling further when the corpus luteum regresses (McClure et al 1994).
These results are concordant with those of a recent report in the rhesus
monkey, in demonstrating a high degree of endothelial cell proliferation as the
corpus luteum forms (Christenson and Stouffer 1996). The observation of
proliferation in non-endothelial cells has not been previously described in the
human corpus luteum. Our finding that the majority of these cells are non-
steroidogenic is supported by the low incidence of mitotic figures observed in
steroidogenic cells of the corpus luteum (Corner 1956).
3.4.2 Angiogenesis during simulated early pregnancy
Proliferation of luteal cells was examined in hCG stimulated corpora lutea. The
pattern of endothelial cell proliferation in early pregnancy in women has not
been previously described. Both the blood flow to and the steroidogenic output
from the corpus luteum increase with hCG stimulation (Atkinson et al 1975;
Salim et al 1994). However, no increase in either endothelial or non-endothelial
cell proliferation was detected during luteal rescue. Increasing blood supply to
the gland may be mediated by changes in vascular tone at this stage, with
angiogenesis occurring at a later point. Hypertrophy, rather than hyperplasia of
luteal cells may account for the early changes in luteal mass.
3.4.3 Suitability of antibodies
Antibodies directed against vWF and Ki67 were used to demonstrate
endothelial cells and proliferating cells respectively. vWF is an intrinsic clotting
cascade protein and is produced in cells of endothelial lineage. Comparative
studies have shown this antibody to be both sensitive and specific in detecting
endothelial cells (McComb et al 1982).
Ki67 antibody specifically identifies proliferating cells (Gerdes et al 1991) and is
thought to recognise an epitope of a nuclear non-histone protein (Boulton and
Hodgson 1995). Comparison studies in a number of tissues have shown Ki67
immunostaining to compare favourably with the gold standard methods of
bromodeoxyuridine and radiolabeled thymidine incorporation (Sasaki et al
1988; Kamel et al 1989).
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3.4.4 Proliferation throughout the luteal phase
Cell proliferation In the corpus luteum does not appear to be completely limited
to any one stage of the luteal phase. Endothelial cell proliferation persists at a
lower rate through the mid and late luteal phases, when the functional capacity
of the gland is declining, as measured by progesterone and inhibin A production
(lilingworth et al 1990). Similarly, there is still a significant rate of non-
endothelial cell proliferation at these stages. Other investigators have noted
similar levels of cell proliferation in the late luteal phase in human (McClure et al
1994) and rhesus monkey (Christenson and Stouffer 1996). The absence of
further growth of the corpus luteum despite apparent continuing cellular
proliferation implies that there is a simultaneous process of cell loss. Different
forms of cell death in the human and primate corpus luteum have recently been
demonstrated (Funayama et al 1996; Fraser et al, 1995). Indeed high levels of
programmed cell death have been shown to follow induced luteal regression in
primates (Fraser et al 1995; Young et al 1996) while cells with morphology
characteristic of apoptosis have been identified in during luteolysis in the sheep
(O'Shea et al 1977).
3.4.5 Overview
In conclusion, this study has investigated the role of endothelial cell proliferation
in luteal rescue analogous to that of early pregnancy. No differences in the rate
of proliferation of any cell type were found indicating that the luteal rescue of
pregnancy is not due to enhanced rates of cellular proliferation.
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Figure 3.1
Photomicrographs of serial sections from early(a), mid (d), late, (c) and rescued
corpora lutea (d).
Serial sections are stained for von Willebrand factor (vWF) and Ki67. Arrows
indicate Ki67 positive cells.




(a) The mean (+/-SE) number of endothelial cells present per high power field
at different stages of the luteal phase.
(b) The mean (+/-SE) number of endothelial cells exhibiting proliferation per
high power field at different stages of the luteal phase.
(c) The mean (+/-SE) number of non-endothelial cells exhibiting proliferation
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79
Figure3.3
Photomicrograph of early luteal phase tissue with dual immunostaining for Ki67
(brown staining) and 3pHSD (red staining). Insert shows negative control
immunostaining. The arrow indicates a cell which exhibits positive
immunostaining for both Ki67 and 3|3HSD.




ANGIOGENIC GROWTH FACTORS IN THE HUMAN CORPUS LUTEUM
4.1 Introduction
4.1.1 Vascular factors and luteal function
Vascular factors may be important for the regulation of luteal function. The
corpus luteum is a highly vascular structure with a blood flow which is, per unit
weight, the highest of any tissue in the body (Reynolds et al 1992; Bruce and
Moor 1972; Bruce et al 1984; Wiltbank et al 1988). A dense network of luteal
vessels develops during the first three days after ovulation, and grows from the
theca lutein cell layer to supply the previously avascular granulosa lutein cells
(Corner 1956; Zheng et al 1994). Proliferation of endothelial cells in the human
corpus luteum is maximal as the corpus luteum forms following the LH surge.
(Rodger et al 1997, see chapter 3). Although Ghinea et al (1994) have
described the presence of LH binding sites in endothelial ceils in the rat ovary,
Duncan et al noted in 1996 that human luteal endothelial cells did not express
LH receptor messenger RNA. in order for LH to trigger this angiogenesis, a
paracrine signal must pass between the LH receptor-positive steroidogenic
cells and the endothelial cells of the gland. Local secretion of vascular growth
factors may thus account for the high rate of angiogenesis observed during
establishment of the corpus luteum.
4.1.2 Vascular factors in pregnancy
Proliferation of endothelial cells does not change during hCG simulated early
pregnancy (Rodger et al 1997; Christenson and Stouffer 1996). However it has
been demonstrated that the blood flow to the corpus luteum increases during
early pregnancy (Baber et al 1988; Salim et al 1994; Wiltbank et al 1989),
allowing the delivery of substrates necessary for progesterone biosynthesis.
Luteal blood flow may initially be increased by changes in vascular tone, with
blood vessel growth occurring at a later stage. Upregulation of growth factor
expression may be detectable at an earlier stage than increased rates of
endothelial cell proliferation.
4.1.3 Angiogenic growth factors
Bovine, ovine and porcine ovaries produce angiogenic factors throughout the
luteal phase and in early pregnancy (Reynolds et al 1992; 1994; Ricke et al
1995; Grazul-Bilska et al 1992). Analysis of ovine and bovine luteal extracts has
led to the identification of two heparin-binding angiogenic growth factors
(Grazul-Bilska et al 1993;1995; Doraiswamy et al 1995a;b).
4.1.4 Basic fibroblast growth factor (bFGF)
bFGF promotes angiogenesis by acting through membrane receptors to
increase the rate of endothelial cell proliferation (Bagavandross and Wilkes
1991). In other tissues, bFGF and its receptors are localised in the endothelial
cell compartment (Bikfalvi et al 1997). bFGF activity has been detected in
bovine corpora lutea (Grazul-Bilska et al 1993) and bFGF has been localised in
bovine endothelial and steroidogenic luteal cells (Schams et al 1994). In
addition, bFGF receptors 1 and 2 have been immunolocalised to both
endothelial and steroidogenic cells of bovine corpora lutea (Doraiswamy et al
1995b; Redmer and Reynolds 1996).
4.1.5 Vascular endothelial growth factor (VEGF)
Vascular endothelial growth factor (VEGF) stimulates angiogenesis by
increasing endothelial cell mitosis and vascular permeability (Ferrara and
Davis-Smith 1997; Roberts et al 1995), and acts in synergy with bFGF (Stavri et
al 1995). Increased vascular permeability allows fibrin deposition providing a
framework for blood vessel formation. Although previous studies have localised
VEGF to perivascular cells in domestic species (Doraiswamy et al 1996) VEGF
has been immunolocalised in steroidogenic luteal cells in primates (Kamat et al
1995; Gordon et al 1996). VEGF has been shown to act through two tyrosine
kinase linked receptors, fit and kdr, which are present on endothelial cell
membranes in other tissues (Ferrara et al 1997). Fluctuations in levels of these
growth factors or their receptors may affect the rate of luteal angiogenesis
which may in turn influence luteal function.
4.1.6 Regulation of growth factors by the hypothalamic-pituitary axis.
VEGF secretion by the corpus luteum may be regulated by the hypothalamic-
pituitary axis in primates, as administration of GnRH antagonist to rhesus
monkeys has been shown to result in a decrease in VEGF mRNA expression
(Ravindranath et al 1992b). Although hCG induced VEGF secretion has been
demonstrated in luteinised granulosa cells in vitro (Neulen et al 1995), and hCG
administration has been shown to increase urinary VEGF output in women
(Roberts and Palade 1995) the distribution of these growth factors in the corpus
luteum of early pregnancy or during luteal regression in women is unknown.
4.1.7 Aims of this chapter
This chapter aims to determine whether production of VEGF or bFGF vary
according to luteal function. Immunohistochemistry, protein electrophoresis
and in situ hybridisation studies were utilised to investigate whether the
distribution or localisation of these factors changed throughout the luteal phase




Sections (5[xm) were cut, air-dried at 56°C, dewaxed in xylene then rehydrated
in 100%, 95%, and 70% ethanol. Sections were exposed to three 5 minute
cycles of microwave irradiation at 700w, in citrate buffer 0.01 M, pH 6.0 (Shi et
al 1993). Sections were preabsorbed for 20 minutes with normal goat serum
(SAPU, Carluke, UK) diluted 1:5 in tris buffered saline. The primary antibody, a
polyclonal antibody raised in rabbit against human VEGF protein (Santa Cruz,
Santa Cruz, CA, USA) was applied at 1:100 dilution (0.5 mg/mL protein
concentration). For control sections, 0.5 mg/mL of rabbit serum (Dako, High
Wycombe, UK) was used in place of primary antibody. After incubation for 20
hours at 4°C, the secondary antibody, biotinylated goat anti rabbit (Dako) was
applied at a dilution of 1:500 for 45 minutes. Colouring was obtained with
Vector Red chromogen (Vector, Peterborough, UK) by means of a reaction with
avidin covalently coupled to alkaline phosphatase (Dako).
In order to identify the nature of cells staining positively for VEGF, sections
serial to those immunostained for VEGF were immunostained for P450C17.
This enzyme is specifically localised in theca lutein cells (Sasano et al 1989).
Sections were blocked with normal swine serum diluted 1:5 in tris buffered
saline. Polyclonal 17-alpha hydroxylase cytochrome P450 antibody, raised in
rabbit, (gift of Prof M Waterman, Vanderbilt University, Nashville), was applied
at 1:750 dilution, and sections were incubated at 4°C for 20 hours. Biotinylated
swine anti-rabbit secondary antibody (Dako) at a dilution of 1:500 was then
applied for 30 minutes. Colouring was obtained with nitroblue tetrazium chloride
(NBT) by means of a reaction with avidin covalently coupled to alkaline
phosphatase.
Control sections were incubated with normal rabbit serum (Dako) at 1:750
dilution in place of 17-alpha hydroxylase primary antibody.
The intensity of immunostaining for VEGF at different stages of luteal function
was assessed in four low power (x100) fields from opposite quadrants of the
glandular component of the section. Staining was graded as follows: 0= no
staining; 1= weak staining; 2= moderate staining; 3= deeper immunostaining,
4= intense immunostaining (figure 2). In all cases the observer was unaware of
the nature of the section being examined. Differences in the intensity of staining
were investigated by one-way analysis of variance using stage of the luteal
phase as a between subject (corpus luteum) variable. The intensity of
immunostaining in late and rescued corpora lutea was also compared in the
same manner.
Immunohistochemistry for bFGF was carried out using the same methodology
as for VEGF using a mouse monoclonal antibody directed against human bFGF
(Upstate Biotech, Madison, NY, USA) at a dilution of 1:100 (5mg/mL). Negative
control sections were incubated with mouse IgG at a 5mg/mL concentration in
place of the primary antibody. After application of rabbit anti-mouse biotinylated
secondary antibody staining was visualised by means of a reaction with avidin
covalently coupled to horseradish peroxidase (DAKO).
4.2.2 SDS-PAGE and immunoblotting
Protein was extracted from eight corpora lutea (2 early, 2 mid, 2 late and 2
rescued). Tissue was solubilised in 0.1% SDS buffer at 4°C, sonicated and
centrifuged for 5 minutes. Supernatant was stored in aliquots at -20°C prior to
use. Protein content in the homogenates was determined by Bradford's method
using a commercial kit (Bradford 1976), (Biorad, Flercules, CA, USA). For
polyacrylamide gel electrophoresis (PAGE), 200|ig samples were denatured by
boiling for five minutes in an equal volume of sample buffer containing 5% |3-
mercaptoethanol and run on an 11% polyacrylamide gel alongside molecular
weight markers (Rainbow markers, Biorad). Gels were hybridised to a
nitrocellulose membrane (Flybond C, Amersham International,
Buckinghamshire, UK) for 18 hours at 50 volts. Western blots obtained were
analysed for (1) VEGF protein with polyclonal VEGF antibody at 1:500 dilution
and (2) bFGF using monoclonal bFGF antibody at a dilution of 1:500. Proteins
were detected with diaminobenzidene by means of a reaction with avidin
covalently coupled to horseradish peroxidase (Dako).
4.2.3 In situ hybridisation
In order to confirm the distribution of VEGF staining, in situ-hybridisation studies
for VEGF and also for fit, a VEGF receptor, were undertaken.
For in situ hybridisation, radial segments from eight corpora lutea, and also
from human term placenta (to be used as a positive control tissue) were frozen
in mounting medium as described in chapter 2 and stored at -70 °C. Frozen
sections (5|xm) were attached to sterile TESPA coated glass slides, and fixed in
4% paraformaldehyde for 5 minutes. The VEGF and fit probes (Sharkey et al
1993; Cooper et al 1995) were generated from a 753 base and 272 base pair
fragments respectively in pcDNAIII plasmid (Promega, Madison, Wl, USA). To
obtain antisense and sense probe templates the plasmid was lysed by Ecl-xlX
and Xhol restriction endonuclease digestion (Boehringer Mannheim,
Mannheim, Germany) and purified. Antisense and sense labelled riboprobes for
VEGF were synthesised via incorporation of 35S-UTP (Amersham International)
by addition of T3 or T7 polymerases (Promega). Similarly, antisense and sense
fit probes were synthesised by addition of T7 or T3 polymerases respectively.
The probes were then treated with ribonuclease-free DNasel (Promega), and
hybridisation was carried out at 55°C for 20 hours. Sections were subjected to
washes of increasing stringency, culminating in a high stringency wash for 30
minutes at 70°C in a solution containing 2mM dithiotreitol and 0.1 M standard
saline citrate. Autoradiography was carried out using NTB emulsion (Kodak,
Rochester, NY, USA). The emulsion coated slides were stored at 4°C with
desiccant for an exposure time of 6 weeks. The slides were developed in Kodak
D19 developer, counterstained with haematoxylin and mounted.
4.3 Results
4.3.1 Immunohistochemistry
Immunostaining for VEGF was identified in all corpora lutea examined (figure
4.1). Immunostaining was localised in theca and granulosa lutein cells
throughout the luteal phase and in simulated early pregnancy. In each case,
staining of theca lutein cells was of higher intensity than that of granulosa lutein
cells. Immunostaining for VEGF was present in all theca lutein cells of the
corpora lutea at all stages of the luteal phase and in simulated early pregnancy.
Granulosa lutein cells stained homogeneously for VEGF in the early, mid and
late luteal phases, but staining became patchy in hCG treated corpora lutea,
where individual granulosa lutein cells stained strongly for VEGF while adjacent
cells were only weakly positive. Overall intensity of immunostaining for VEGF
did not vary significantly between different stages of luteal function (figure 4.2).
Endothelial cells did not exhibit immunostaining for VEGF at any stage of the
luteal phase.
Immunostaining for bFGF was in contrast localised in endothelial cells of a
minority of luteal blood vessels (figure 4.3). No immunostaining for bFGF was
detected in steroidogenic luteal cells. Vessels with positive bFGF
immunostaining were located at the periphery of the gland and had muscular
walls.
4.3.2 SDS-PAGE and Immunoblotting
A 40kDa protein band, consistent with VEGF (Ferrara and Davis-Smith 1997)),
was observed at all stages of luteal function. The intensity of the band did not
change throughout the luteal phase or in simulated early pregnancy (figure 4.4).
An 18kDa protein band, consistent with bFGF (Bikfalvi et al 1997), was
detected at all stages of luteal function. The intensity of the band did not
change throughout the luteal phase or in simulated early pregnancy. A larger
24kDa band, consistent with a nuclear form of bFGF (Ferrara and Davis-Smith
1997) was similarly detected at all stages of luteal function (figure 4,5).
4.3.3 In situ-hybridisation
Hybridisation of antisense VEGF probe to tissue sections was localised
predominantly in theca lutein cells. No such hybridisation was evident in control
sections incubated with sense riboprobe (figure 4.6).
In positive control tissue VEGF antisense hybridisation was present in
syncytiotrophoblast as previously reported (Shiraishi et al 1996). No such
hybridisation was observed with sense riboprobe (figure 4.7).
Hybridisation of antisense probe to fit, a VEGF receptor, was localised in
endothelial cells of luteal blood vessels in the corpus luteum. No such
hybridisation was detected with sense riboprobe (figure 4.8).
4.4 Discussion
4.4.1 General points
This is the first study to examine distribution of the angiogenic factors VEGF
and bFGF throughout the lifespan of the human corpus luteum and represents
the first description of bFGF localisation in the human corpus luteum. VEGF
was specifically localised in steroidogenic cells of the corpus luteum, while
bFGF was localised in endothelial cells of luteal blood vessels.
This localisation fits with a role in regulation of the luteal vasculature. Luteal
maintenance is associated with increased blood flow and is triggered by hCG
secreted from the feto-piacental unit (Redmer and Reynolds 1996). hCG may
induce changes in blood flow to the corpus luteum by influencing local
production of paracrine regulators of angiogenesis such as VEGF from
steroidogenic cells (Neulen et al 1995). Autocrine secretion of growth factors
such as bFGF may also be important for luteal angiogenesis.
4.4.2 VEGF localisation
A previous study localising VEGF in the human corpus luteum has reported that
this growth factor is localised predominantly in the granulosa lutein cells, with
theca lutein cells containing smaller amounts of VEGF protein (Kamat et al
1995). The current work demonstrates in a wide range of luteal tissue that both
VEGF protein and mRNA are present at higher levels in theca than in granulosa
lutein cells. Blood vessels initially grow into the developing corpus luteum from
invaginations of theca cell rich connective tissue (Corner 1956; Zheng et al
1994). The high level of angiogenesis observed (McClure et al 1994) in these
areas may be due to thecal VEGF production.
Controversy already exists concerning VEGF localisation with the human antral
follicle. Kamat et al (1995) describe VEGF in granulosa cells of ovarian follicles,
while Gordon and co-workers localised VEGF immunostaining to the theca cell
compartment. It is possible that these inconsistencies are due to the existence
of alternatively spliced variants of VEGF. Granulosa and theca lutein cells may
produce different relative quantities of the VEGF forms. Certain antibodies may
not recognise all forms of VEGF, leading to a particular pattern of staining. The
VEGF antibody used in this study was polyclonal and was directed against a 21
amino-acid sequence from the N-terminal of VEGF, a region common to all
forms of the protein.
The localisation of VEGF to theca cells of the corpus luteum described above is
confirmed by in situ hybridisation using a probe common to all VEGF splice
variants. In addition, SDS-PAGE and immunoblotting validates that the antibody
used detects a protein of a size consistent with VEGF.
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4.4.3 VEGF and changing luteal function
Levels of VEGF production did not change throughout the luteal phase or in
simulated early pregnancy. In contrast to in vitro studies, hCG administration
did not increase VEGF production. VEGF may be of importance in maintaining
the luteal vasculature during the lifespan of the gland, but is unlikely to be
involved in regulation of luteal function.
In situ hybridisation studies localised fit, a VEGF receptor, in endothelial cells of
small vessels within luteal tissue. This distribution is consistent with a paracrine
mode of action for VEGF in the corpus luteum. Varying expression of the VEGF
receptors fit and kdr may regulate the angiogenic potential of the gland at
different stages of luteal function. Further work is required to elucidate the
distribution and level of expression of these receptors throughout the lifespan of
the corpus luteum and in simulated early pregnancy.
4.4.4 bFGF localisation
In contrast to VEGF distribution, bFGF was immunolocalised in endothelial cells
of peripheral luteal blood vessels. In other tissues bFGF is also present in
endothelial cells, and the bFGF receptors are localised on endothelial cell
membranes, suggesting an autocrine role for this growth factor. In addition,
bFGF receptors have been identified on steroidogenic as well as endothelial
cells in the bovine corpus luteum. The effects of bFGF on steroidogenic cell
function are unknown. Further work is required to establish the localisation of
the bFGF receptor in the human corpus luteum.
4.4.5 bFGF and changing luteal function.
Immunoblotting detected both nuclear and cytoplasmic forms of bFGF protein
at all stages of luteal function and in simulated early pregnancy. Consistent
levels of bFGF production during luteal maintenance and regression imply that
this growth factor is not directly involved in the control of luteal function. bFGF
may instead play a role in the maintenance of the vasculature of the corpus
luteum throughout its lifespan. As previously discussed for VEGF, changes in
bFGF receptor number or distribution may be implicated in regulating luteal
function.
4.4.6 Overview
In summary, VEGF is produced by theca and granulosa lutein cells in the
human corpus luteum throughout the luteal phase and in simulated early
pregnancy. Fit, a VEGF receptor, is located on endothelial cells of luteal blood
vessels. VEGF may act in a paracrine manner to maintain the vasculature of
the corpus luteum throughout its lifespan. Unchanging production of VEGF
during luteal regression and maintenance suggest that this growth factor is not
a direct regulator of luteal lifespan.
Localisation of bFGF in endothelial cells is consistent with an autocrine role for
this growth factor in the maintenance of the luteal vasculature. Consistent
bFGF production throughout the luteal phase and in simulated early pregnancy




The bar in each case represents 50^m
Immunostaining for VEGF in early, mid, late and rescued corpora lutea. VEGF
immunostaining is of greater intensity in theca lutein (T) than in granulosa lutein
cells (G). The more intense thecal staining corresponds to immunostaining for
P450C17 which is specific to theca cells (b) (brown immunostaining). Intense
thecal staining for VEGF is evident in a high power view (a). Inserts show
negative control sections, incubated with non-immune serum in place of primary
antibody, and are free from staining in each case.
 
Figure 4.2
Graphical representation of intensity of VEGF immunostaining in theca lutein
(solid) and granulosa lutein (shaded) cells throughout the luteal phase and in
simulated early pregnancy. At all stages immunostaining for VEGF was more
intense in theca than in granulosa cells; immunostaining intensity did not
change significantly with changing luteal function.
for VEGF throughout the luteal phase
Stage of luteal phase
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Figure 4.3
Immunostaining for bFGF in a section of late luteal phase corpus luteum (a).
Immunostaining is localised in a small blood vessels with muscular walls at the
periphery of the gland. The scale bar represents 50^im. Figure (b) shows a
negative control section, incubated with non-immune serum in place of primary
antibody, and is free from staining.
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Figure 4.4
SDS-PAGE and immunoblotting for VEGF in the human corpus luteum.
Samples are denoted as follows: E- early, M-mid, L-late, R-rescued corpora
lutea. A single protein band was identified at 40kDa consistent with VEGF.
Larger bands are due to non-specific staining of albumin and IgGs.
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Figure 4.5
SDS-PAGE and immunoblotting for bFGF throughout the luteal phase. Protein
samples are denoted as follows; E-early, M-mid, L-late, R- rescued luteal.
Protein bands were visible at 18 and 24 kDa, consistent with previously




SDS-PAGE and immunoblotting for bFGF in the human corpus luteum
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Figure 4.6
In situ hybridisation for VEGF in corpus luteum from the early luteal phase. Top
section shows hybridisation of antisense riboprobe under dark field illumination;
middle section shows the same section under light field illlumination; lower plate
illustrates binding of sense riboprobe under dark field illumination in a negative




In situ hybridisation for VEGF in placenta (positive control tissue). Top section
shows hybridisation of antisense riboprobe under dark field illumination; middle
plate shows the same section under light field ililumination; lower plate
illustrates binding of sense riboprobe under dark field illumination in a negative




In situ hybridisation for fit, a VEGF receptor in corpus luteum from the early
luteal phase. Hybridisation with antisense probe is localised in luteal blood
vessels, top plate; middle plate shows the same section under light field
illlumination; lower plate illustrates binding of sense riboprobe under dark field




CONTROL OF APOPTOSIS IN THE HUMAN CORPUS LUTEUM
5.1 Introduction
5.1.1 Cell death and luteal regression
During the process of luteolysis, the corpus luteum undergoes a loss of function
and structure over a short period of time. Recent studies suggest that cell death
may be involved in luteal regression. Different forms of cell death including
necrosis and autophagocytosis (Fraser et al 1995) and apoptosis (Shikone et
al 1996; Young et al 1996; Modlich et al 1996) have been described during
luteolysis. A high rate of cell death at the end of the luteal phase could account
for the rapid diminution in the function and structure of the gland which is
observed at this time. A high rate of cell death may cancel out the continuing
proliferation observed in the corpus luteum during functional regression
(Rodger et al 1997). The presence of hCG in early pregnancy may result in
reduced rates of luteal cell death which may allow luteal growth without
increased proliferation as:
Rate of cell accumulation (tissue growth) = rate of cell proliferation - rate of cell
death. (Reed 1994).
5.1.2 Apoptosis
There is mounting evidence to suggest that programmed cell death may be the
principal form of cell death involved in luteal regression. Apoptosis is a form of
physiological cell death characterised by morphological as well as biochemical
criteria. The cell shrinks and becomes denser while chromatin becomes
pyknotic and marginated in smooth masses against the nuclear membrane
(Manjo and Joris 1995; Kerr et al 1972). In contrast to necrosis, organelles do
not swell. The nucleus may also break up and the cell may form buds
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containing fragments of the nucleus. The buds break away to become
membrane bound dense apoptotic bodies which are then phagocytosed by
tissue macrophages or neighbouring cells. The time course of apoptosis is
swift, with the morphological process taking between 30 minutes and one hour
to complete. Biochemically, the DNA of a cell undergoing apoptosis is broken
down into segments which are multiples of 200 base pairs long
(oligonucleosomes). When run out on a gel, DNA from these cells shows a
characteristic laddering' pattern (Wyllie et al 1980).
DNA cleaved during apoptotic cell death may be detected in situ by 3' end
labelling (Gavrieli et al 1992).
5.1.3 Programmed cell death and luteal regression
Evidence suggesting that apoptosis could be involved in luteal regression
comes from a number of sources.
There are morphological similarities between luteolysis and apoptosis,
including progressive macrophage infiltration (Lei et al 1991) and nuclear and
cytoplasmic condensation (Gillim et al 1969). Such changes were noted in the
regressing corpus luteum even before the term 'apoptosis' was coined, (Corner
1956; O'Shea 1977) and are present in steroidogenic and endothelial cells of
the gland.
Nucleosomal DNA breakdown was first demonstrated in luteinised granulosa
cells in the rat (Zeleznik et al 1989) and has since been demonstrated during
spontaneous or induced luteolysis in the cow (Juengel et al 1993), marmoset
(Young et al 1996) and human (Shikone et al 1996).
3' end labelling of DNA in apoptotic cells has been demonstrated during
luteolysis in women and primates (Young et al 1996; Shikone et al 1996;
Funayama et al 1996). The majority of apoptotic cells identified with this method
belong to the steroidogenic cell compartment. Cyclical changes in the rate of
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apoptosis are thought to play a part in the regulation of other hormone
dependant tissues such as endometrium and breast.
5.1.4 Control of programmed cell death
The control of apoptotic rates during luteal maintenance or regression may play
a major role in regulating luteal lifespan.
Programmed cell death is controlled by the expression of a number of
regulatory genes including c-myc, p53 and AP01/fas (Osborne and Schwartz
1994). In particular, it has been suggested that an interaction between the
proto-oncogene c-myc, and members of the bcl-2 family may be of importance
in controlling the rate of apoptosis (Bissonette et al 1992). C-myc expression
moves the cell to a position where a choice between proliferation or death must
be made. The fate of the cell then depends upon external factors such as the
availability of growth factors or internal factors such as the expression of bcl-2
family proto-oncogenes. In the course of our studies c-myc has been
demonstrated in the human corpus luteum, although the level of expression
remains unchanged throughout the luteal phase (lllingworth et al 1994).
5.1.5 Bcl-2 family of proto-oncogenes
Bcl-2 is one of an expanding family of regulatory proteins and is found in
mitochondrial, endoplasmic reticulum and nuclear membranes (Hockenbery et
al 1990; Monaghan et al 1992). The bcl-2 gene was first identified from the
t(14;18) breakpoint in human follicular lymphoma (Tsujimoto and Croce 1986),
and is of particular interest with respect to the rescue of the corpus luteum as it
is known to protect against apoptosis (Vaux et al 1988). It has recently been
demonstrated that bcl-2 expression may be involved in the selection of ovarian
follicles (Tilly 1993) and in the control of the endometrium (Gompel et al 1994).
It is now apparent that an essential component of bcl-2 function is its interaction
with bax, a 21kda protein with a degree of homology to bcl-2. Bcl-2 is thought to
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form heterodimers with bax, resulting in a loss of its protective effect. Bax itself
forms homodimers which induce apoptosis. It appears to be the relative ratios
of bcl-2 and bax that will determine the fate of a cell, rather than the absolute
levels of either (Oltvai et al 1993; Yin et al 1994). Other bax-like proteins exist
which can influence the fate of a cell in different ways (Boise et al 1993 ; Nunez
and Clarke 1994).
In the follicle, a decrease in the bcl-2 to bax ratio favours atresia, and similar
mechanisms may extend beyond ovulation to govern the fate of the corpus
luteum. Indeed, bax expression has recently been shown to be upregulated
towards the end of the luteal phase in the cow (Rueda et al 1997), and it is
possible that changes in bcl-2 or bax expression at the end of the luteal phase
could influence the fate of the gland.
5.1.6 Aims of this chapter
This chapter investigates whether bcl-2 and bax are involved in the regulation
of luteal lifespan in women. Immunohistochemistry, protein electrophoresis and
the polymerase chain reaction were used to examine bcl-2 and bax expression
in corpora lutea retrieved at different stages of the luteal phase as well as after
treatment with hCG to mimic luteal rescue in early pregnancy. In addition, the
production of bcl-2 protein during induced luteal regression was studied in the
marmoset monkey by SDS-PAGE and immunoblotting.
5.2 Materials and Methods
5.2.1 Bcl-2 immunohistochemistry
Sections (5^) were cut, air-dried at 56°C, dewaxed in xylene then rehydrated
in 100%, 95%, and 70% ethanol. Sections were exposed to three 5 minute
cycles of microwave irradiation at 700w, in citrate buffer 0.01 M, pH 6.0 (Shi et
al 1993). Endogenous peroxidase activity was inhibited using 0.3% hydrogen
peroxide in methanol for 30 minutes and the sections were preabsorbed for 20
minutes with normal horse serum (Vector, Peterborough, UK). The primary
antibody, a monoclonal antibody against a peptide corresponding to amino
acids 41-54 of human bcl-2 protein (Dako, High Wycombe, UK) was applied at
1:40 dilution (7.5 mg/mL IgG concentration). For control sections, 7.5 mg/mL of
mouse IgG was used in place of primary antibody. After incubation for 20 hours
at 4°C, the secondary antibody, biotinylated horse anti-mouse antibody
(Vector) was applied for 45 minutes. Colouring was obtained with
diaminobenzidine by means of a reaction with avidin covalently coupled to
horseradish peroxidase (Vector).
In order to establish which luteal cells localise bcl-2 immunohistochemical
colocalisation of bcl-2 and 17-alpha hydroxylase cytochrome P450 was
undertaken. 17-alpha hydroxylase is located specifically in the theca lutein
cells. (Sasano et al 1989). Eight sections of corpus luteum (2 early, 2 mid, 2
late luteal and 2 rescued) were examined. Sections were dual immunostained
for bcl-2 and 17-alpha hydroxylase. Briefly, sections underwent
immunohistochemistry for bcl-2 according to the protocol above, using
diaminobenzidine as the chromogen. Sections were then blocked with normal
swine serum diluted 1:5 in tris buffered saline. Polyclonal 17-alpha hydroxylase
cytochrome P450 antibody, raised in a rabbit, (gift of Prof M Waterman,
Vanderbilt University, Nashville), was applied at 1:750 dilution, and sections
were incubated at 4°C for 20 hours. Biotinylated swine anti-rabbit secondary
antibody (Dako) at a dilution of 1:500 was then applied for 30 minutes.
Colouring was obtained with nitroblue tetrazium chloride (NBT) by means of a
reaction with avidin covalently coupled to alkaline phosphatase (Vector).
Control sections were incubated with normal rabbit serum (Dako) at 1:750
dilution in place of 17-alpha hydroxylase primary antibody.
Staining intensity for bcl-2 was judged by eye by two independent assessors.
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5.2.2 SDS-PAGE and immunoblotting
Protein was extracted from eight corpora lutea (2 early, 2 mid, 2 late and 2
rescued). Protein extracted from tonsil was used as a positive control. Tissue
was solubilised in 0.1% SDS buffer at 4°C, sonicated and centrifuged for 5
minutes. Supernatant was stored in aliquots at -20°C prior to use. Protein
content in the homogenates was determined by Bradford's method using a
commercial kit (Bradford 1976; Biorad, Hercules, CA, USA). For polyacrylamide
gel electrophoresis (PAGE), 200|ag samples were denatured by boiling for five
minutes in an equal volume of sample buffer containing 5% p-mercaptoethanol
and run on an 11% polyacrylamide gel. Gels were hybridised to a nitrocellulose
membrane (Hybond, Amersham International; Buckinghamshire, UK) for 18
hours at 50 volts. Membranes were then were analysed for bcl-2 protein with
monoclonal bcl-2 antibody at 1:500 dilution. Proteins were detected with a
chemiluminesence technique by means of a sheep antimouse HRP linked
antibody (Amersham International).
5.2.3 PCR for bcl-2
Total RNA was extracted from eight corpora lutea (2 early, 2 mid, 2 late and 2
rescued) and one specimen of human tonsil by the method of Chomczynski and
Saatchi (1987). The quantity and purity of the nucleic acid preparations were
estimated by measuring the optical density of each sample at 260 vs. 280nm.
Total RNA was reverse transcribed into first strand cDNA using
oligo(deoxythymidine)-primer (Clontech, Palo Alto, CA, USA) and MMLV-
reverse transcriptase (Clontech). Oligonucleotide primers were synthesised
based on the human bcl-2 cDNA sequence as follows 5'
ACCTGGATGTTCTGTGCC 3', and 5' CTCAGACAGAGCCAGTATTGG 3'. The
first strand of cDNA was subjected to 30 cycles of PCR amplification (1 min
denaturation at 94°C, 1 min annealing at 70°C and 1 minute extension at 72°C)
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and the amplified products were resolved through 1.5% agarose gels. The
identity of the 515 base pair amplified product was confirmed by restriction
digestion with Hinc II endonuclease.
5.2.4 SDS-PAGE and immunoblotting for bcl-2 during induced luteal
regression in the marmoset monkey.
Protein was extracted from eight marmoset ovaries containing corpora lutea. (3
were retrieved from pregnant animals, 2 from non-pregnant control animals, 2
which were retrieved after treatment with PGF2ato induce luteal regression
and 1 from an animal which had received GnRH antagonist treatment to induce
luteal regression.) In addition, protein was extracted from marmoset thymus for
use as a positive control. Tissue was solubilised in 0.1% SDS buffer at 4°C,
sonicated and centrifuged for 5 minutes. Supernatant was stored in aliquots at
-20°C prior to use. Protein content in the homogenates was determined by
Bradford's method using a commercial kit (Bradford 1976; Biorad). For
polyacrylamide gel electrophoresis, 200|j,g samples were denatured by boiling
for five minutes in an equal volume of sample buffer containing 5% p-
mercaptoethanol and run on an 11% polyacrylamide gel for 6 hours at 180
volts. Gels were hybridised to a nitrocellulose membrane (Amersham
International) for 18 hours at 50 volts. Western blots obtained were analysed for
bcl-2 protein with polyclonal bcl-2 antibody at 1:500 dilution. Proteins were
detected by means of an avidin/biotin linked alkaline phosphatase system
(Dako) which reacted with Nitroblue tetrazium chloride (NBT) to give a blue
colour.
5.2.5 Bax immunohistochemistry
Sections (5[im) were cut, air-dried at 56°C, dewaxed in xylene then rehydrated
in 100%, 95%, and 70% ethanol. Sections were exposed to three 5 minute
cycles of microwave irradiation at 700w in distilled water (Krajewski et al
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1994a). Sections were preabsorbed for 20 minutes with normal goat serum
(SAPU, Carluke ,UK). The primary antibody, a polyclonal antibody directed
against a peptide corresponding to amino acids 43-61 of mouse bax protein
(Krajewski et al 1994a) was applied at 1:500 dilution. For control sections,
normal rabbit serum at a 1:500 dilution was used in place of primary antibody.
After incubation for 20 hours at 21 °C, the secondary antibody, biotinylated goat
anti-rabbit (Dako) was applied for 45 minutes. Colouring was obtained with
Vector Red chromogen by means of a reaction with avidin covalently coupled to
alkaline phosphatase.
Staining intensity for bax was judged by eye by two independent assessors.
In order to establish the nature of the luteal cells which stained positively for
bax immunohistochemistry for 17-alpha hydroxylase cytochrome P450 was
undertaken in adjacent sections to those immunostained for bax. Eight sections
of corpus luteum (2 early, 2 mid, 2 late luteal and 2 rescued) were examined.
Sections were blocked with normal swine serum diluted 1:5 in tris buffered
saline. Polyclonal 17-alpha hydroxylase cytochrome P450 antibody, raised in a
rabbit, (gift of Prof M Waterman, Vanderbilt University, Nashville, USA), was
applied at 1:750 dilution, and sections were incubated at 4°C for 20 hours.
Biotinylated swine anti-rabbit secondary antibody (Dako) at a dilution of 1:500
was then applied for 30 minutes. Colouring was obtained with nitroblue
tetrazium chloride (NBT) by means of a reaction with avidin covalently coupled
to alkaline phosphatase.
Control sections were incubated with nonimmune rabbit serum (Dako) at 1:750
dilution in place of 17-alpha hydroxylase primary antibody.
5.2.6 SDS-PAGE and immunoblotting for bax
Protein was extracted from eight corpora lutea (2 early, 2 mid, 2 late and 2
rescued). Tissue was solubilised in 0.1% SDS buffer at 4°C, sonicated and
centrifuged for 5 minutes. Supernatant was stored in aliquots at -20°C prior to
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use. Protein content in the homogenates was determined by Bradford's method
using a commercial kit (Bradford 1976; Biorad). 200|ig protein samples were
denatured by boiling for five minutes in an equal volume of sample buffer
containing 5% p-mercaptoethanol and run on an 11% polyacrylamide gel. Gels
were hybridised to a nitrocellulose membrane for 18 hours at 50 volts. Western
blots obtained (Hybond, Amersham International), were analysed for bax
protein with polyclonal bax antibody at 1:2000 dilution. Protein bands were
visualised using an avidin/biotin linked horseradish peroxidase system (Dako).
5.2.7 PCR for bax
Total RNA was extracted from eight corpora lutea (2 early, 2 mid, 2 late and 2
rescued) by the method of Chomczynski and Saatchi (1987). The quantity and
purity of the nucleic acid preparations were estimated by measuring the optical
density of each sample at 260 vs. 280nm. Total RNA was reverse transcribed
into first strand cDNA using oligo(deoxythymidine)-primer and MMLV-reverse
transcriptase (Clontech). Oligonucleotide primers were synthesised based on
the human bax cDNA sequence as follows 5' TTCTGACGGCAACTTCACTGG
3', and 5' GCCACAAAGATGGTCACG 3'. The first strand of cDNA was
subjected to 30 cycles of PCR amplification (1 min denaturation at 94°C, 1 min
annealing at 53°C and 1 minute extension at 72°C) and the amplified products
were resolved through 1.5% agarose gels. The identity of the 223 base pair
amplified product was confirmed by restriction digestion with BamH1
endonuclease.
In order to ensure that equivalent quantities of cDNA were used for each
reaction, a control PCR reaction was undertaken using primers based on




Photomicrographs of early, mid, late and rescued corpora lutea are shown in
figure 5.1 along with control sections obtained with mouse IgG. Positive staining
for bcl-2 was found in corpora lutea from all stages of the menstrual cycle
including those where maintenance of luteal function with hCG had been
performed. Negative control sections were consistently free of staining. Theca
lutein cells were identified by double staining for 17-alpha hydroxylase, while
granulosa lutein cells were identified on morphological grounds. Examination of
double stained sections revealed that all granulosa lutein cells and a majority of
theca lutein cells exhibited specific staining for bcl-2.
No difference was observed in the intensity or localisation of immunostaining for
bcl-2 between corpora lutea from different stages of the luteal phase. There
was no change in the intensity of immunostaining in the hCG rescued corpora
lutea.
Bcl-2 localisation was also observed in some of the vessels at the periphery of
the parenchymal cells of the corpus luteum. Where such staining was present,
it occurred in all endothelial cells of a sectioned vessel. The remaining vessels
remained free from staining. The proportion of vessels staining positively for
bcl-2 varied from 5% to 15% in individual sections. Variations in this proportion
were unrelated to the stage of the luteal phase. There was no change in either
the number of cells exhibiting 17-alpha hydroxylase staining or the intensity of
staining throughout the luteal phase.
5.3.2 SDS-PAGE and immunoblotting for bcl-2
A single 26kDa band consistent with bcl-2 protein was detected by
immunoblotting in all corpora lutea tissue extracts and in tonsil. As can be seen
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in figure 5.2, small variations in band intensity were noted but these were
unrelated to timing of the sample in the luteal phase.
5.3.3 PCR for bcl-2
A 515 base pair product consistent with bcl-2 was identified after PCR in
samples containing cDNA from human tonsil. No such band was present after
PCR in samples containing human luteal cDNA. Identity of the product as bcl-2
was confirmed by restriction digestion with Hinc II.
5.3.4 SDS-PAGE and immunoblotting for bcl-2 during induced luteal
regression in the marmoset monkey.
A single 26kDa band consistent with bcl-2 was present in the lane containing
protein extracted from marmoset thymus. In lanes from marmoset ovary no
such bands were present. Marmoset ovary proteins exhibited a band reacting
with polyclonal bcl-2 antibody at 31 and 36kDa, with variable numbers of
smaller bands at higher molecular weights (figure 5.3).
5.3.5 Bax immunohistochemistry
Immunostaining for bax was observed in all of the sections examined. Staining
was identified in granulosa and theca lutein cells. All cells morphologically
identified as granulosa cells immunostained for bax. Between 40 and 60% of
granulosa lutein cells stained strongly for bax (figure 5.4), with the remainder
containing weaker immunostaining. Theca lutein cells also contained bax
immunostaining at similar intensity to that of granulosa lutein cells (figure 5.5).
Staining intensity was homogenous throughout theca lutein cells.
Immunostaining for bax was also identified in 5-15% of blood vessels at the
periphery of the gland (figure 5.4). Negative control sections incubated with
nonimmune serum in place of primary antibody were consistently free from
immunostaining (figures 5.4,5.5). Theca lutein cells were identified by staining
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for 17-alpha hydroxylase, while granulosa lutein cells were identified on
morphological grounds.
No differences were found in the number of steroidogenic cells staining
positively for bax protein, nor the intensity of their immunostaining throughout
the luteal phase or in simulated early pregnancy. The number of vessels
staining for bax and the intensity of staining did not vary throughout the luteal
phase or in simulated early pregnancy.
5.3.6 SDS-PAGE and immunoblotting for bax
A 21 kDa protein, consistent with bax (Oltvai et al 1993), was observed at all
stages of the luteal phase in women. Intensity of this band did not vary
throughout the luteal phase or in simulated early pregnancy (figure 5.6).
5.3.7 PCR for bax.
A 233 base pair fragment of cDNA was detected at all stages of the luteal
phase and in simulated early pregnancy (figure 5.7). The identity of the
fragment was confirmed by restriction digestion with BamH1 into two fragments
of 152 and 81 base pairs. PCR for GAPDH control confirmed that equivalent
quantities of cDNA were used in each reaction.
5.4 Discussion
5.4.1 General Points
This is the first demonstration of the bcl-2 family of proto-oncogenes in the
human corpus luteum. Bcl-2 was localised specifically by
immunohistochemistry to steroid secreting cells, and the identity of the protein
was confirmed by a 26kDa protein band on gel electrophoresis in the human
corpus luteum. Bax was similarly localized to the steroidogenic cells of the
gland, with identity of the protein detected confirmed by detection of a 21 kDa
band on protein electrophoresis.
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5.4.2 Bcl-2 localisation in steroid secreting cells.
Bcl-2 immunostaining was consistently localised in the cytoplasm of granulosa
cells. All cells identifiable as granulosa cells by morphology stained positively
for bcl-2. In addition, small clusters of theca lutein cells exhibited bcl-2 staining.
Approximately 10% of blood vessels contained bcl-2 immunostaining. No
staining was present in supporting cells. The presence of bcl-2 in the steroid
secreting cells of the corpus luteum suggests a potential functional role.
Bcl-2 is known to protect against programmed cell death triggered by a wide
range of factors (Reed 1994). Some of these factors, for example c-myc,
tumour necrosis factor a and reactive oxygen species, have been implicated in
luteolysis (Behrman et al 1993). Bcl-2 may prevent death of functional luteal
cells that would otherwise occur in response to such stimuli.
5.4.3 Bax localisation in steroid secreting cells
Bax protein was consistently localised in the cytoplasm of granulosa lutein cells,
theca lutein cells and a proportion of blood vessels. This pattern of
immunostaining is similar to the distribution of bcl-2 in the human corpus
luteum, and may indicate that bcl-2 and bax interact to cause changes in
apoptotic rates in vivo. Staining intensity varied between granulosa lutein cells
within each section, but no morphological differences were detected between
granulosa lutein cells which stained strongly or weakly for bax. Upregulation of
bax expression of bax prior to apoptosis in specific granulosa lutein cells may
result in increased bax immunostaining in particular cells.
5.4.4 Proto-oncogenes in the luteal vasculature
Moderate immunostaining for bcl-2 and bax was also seen in the vascular
endothelium of some luteal arterioles and venules at the periphery of the gland,
while other vessels remained free from staining. There were no apparent
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morphological differences between vessels which exhibited immunostaining
and those which did not. These observations suggest that certain luteal vessels
may be more or less susceptible to apoptotic cell death depending on relative
levels of bcl-2 and bax proteins. Endothelial apoptosis has been observed in
the regressing corpus luteum of sheep and may be responsible for reduced
blood flow to the gland during luteolysis (O'Shea et al 1977). However, as
vascular staining for bcl-2 and bax staining showed little variation throughout
the luteal phase, it is unlikely that such a mechanism would be wholly
responsible for changes in luteal function at the time points examined.
5.4.5 Absolute and relative production of bcl-2 and bax with changing
luteal function.
The process of luteal regression may involve a number of factors. It is possible
that functional luteolysis primarily involves uncoupling of the LH receptor, while
structural luteolysis involves expression or inactivation of proto-oncogenes
involved in apoptosis. A reduction in bcl-2 expression or an increase in bax
expression at the end of the cycle may allow luteolysis to proceed. However, as
described above, there is no significant change in granulosal, thecal or vascular
bcl-2 staining throughout the luteal phase. Corpora lutea which are rescued
with hCG to reproduce the hormonal environment of early pregnancy might be
expected to have increased production of bcl-2 as part of the mechanism which
prevents luteolysis. However, neither the immunohistochemical localisation nor
protein electrophoresis revealed any difference to untreated corpora lutea.
Bax protein and mRNA were detected at all stages of luteal function. In contrast
to recent observations in bovine corpora lutea, there was no increase in bax
expression in the late luteal phase (Rueda et al 1997). This implies that the cell
death which occurs during luteolysis in women is not associated with a gross
change in the bcl-2/ bax ratio.
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5.4.6 Explanations for constant levels of bcl-2 and bax.
Bcl-2 protein may have alternative functions in the human corpus luteum. The
mechanism of action of bcl-2 is poorly understood, but its localisation in the
membranes of the mitochondria, endoplasmic reticulum and nucleus would be
consistent with a role in intracellular transport and regulation. It is possible that
bcl-2 production in the human corpus luteum is not linked to the apoptotic
process, but has an alternative function within the cell.
Bax may also have alternative functions in the human corpus luteum. The
mechanism of action of bax is poorly understood, but as it displays sequence
homology to bcl-2, a role in intracellular transport is possible.
Other members of the bcl-2 family such as mcl-1 (Kozopas et al 1993), bak
(Farrow et al 1995) and bcl-x (Boise et al 1993) can form heterodimers with bax
and bcl-2 as well as acting independently of these factors to promote cell death
or survival. The distribution of such factors within the human corpus luteum is
not known although bcl-x (Krajewski et al 1994b) and mcl-1 (Krajewski et al
1995) have been detected in murine corpora lutea. Such complex interactions
may affect the rate of apoptosis in luteal cells as function of the gland changes.
5.4.7 Bcl-2 production in the marmoset ovary.
Western blotting demonstrated a band consistent with bcl-2 in the marmoset
thymus, but protein bands reacting with this antibody in marmoset ovary were
of a higher molecular weight. There is no published description in any species
of a bcl-2 protein with a molecular weight of 31 or 36kDa. Furthermore, the bcl-
2 antibody detected a 26kDa band consistent with bcl-2 in positive marmoset
thymus, where a high level of bcl-2 expression was expected, demonstrating
that the discrepancy in size is not the result of a species difference in the bcl-2
protein. In the absence of a 26kDa band in marmoset ovary while such a band
is present in thymus it seems unlikely that bcl-2 is present in significant levels in
the marmoset ovary. The larger bands detected may be the result of a cross
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reaction with an unrelated protein, but it is also possible that the bcl-2 antibody
used detects a structurally related member of the bcl-2 family in the marmoset
ovary.
The detection of no bcl-2 in the marmoset ovary by SDS-PAGE and
immunoblotting implies that between primates species differences exist in the
expression of bcl-2 family proto-oncogenes in the ovary.
5.4.8 Overview
In summary, bcl-2 and bax are produced by the granulosa, theca and vascular
endothelial cells of the human corpus luteum. Production does not appear to
change throughout the luteal phase.
Elucidation of the potential roles of proto-oncogenes in the corpus luteum may
require further investigations on the wider bcl-2 family of proto-oncogenes once
the functions of individual members have been clarified.
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Figure 5.1
Photomicrographs of bcl-2 immunostained corpora lutea from throughout the luteal
phase. Section (a) is from a rescued corpus luteum and has been stained for bcl-2.
Granulosa lutein (G) and theca lutein cell (T) staining are demonstrated. Similarly
sections (b), (c), and (d) are stained for bcl-2 and are early, mid and late luteal
respectively. Sections (e) and (f) are mid cycle and are serial to (c); (e) is a negative
control and (f) is double stained for bcl-2 (brown) and 17 alpha hydroxylase (blue).
Sections (g) and (h) are respectively negative control and bcl-2 stained sections
showing vascular endothelial staining.
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Figure 5.2
SDS-PAGE and immunoblotting for bcl-2 throughout the luteal phase. A 26 kDa
protein band consistent with bcl-2 is present in early (E), mid, (M), late (L) and
rescued (R) corpora lutea and also in tonsil (T), used as a positive control tissue.
Molecular weight markers are indicated by numerical values to the left of the figure.
SDS PAGE for bcl-2 in the Human Corpus Luteum
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Figure 5.3
SDS-PAGE arid imunoblotting for bcl-2 in the marmoset ovary. A 26 kDa band,
consistent with bcl-2 is present in human tonsil (T), used as a positive control
tissue. Protein samples from non-pregnant, non treated control marmosets (C),
pregnant marmosets (P) and animals undergoing induced luteal regression (R) in
contrast gave a larger band of approximately 30kDa on immunoblotting.






High power view of bax immunostaining in early (a), mid (b), late (c) and rescued
(d) corpora lutea. Negative control section incubated with non-immune serum in
place of primary antibody (e) is free from immunostaining. Luteal blood vessel (f)
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Figure 5.5
Low power view of bax immunostaining in early, mid, late and rescued corpora
lutea. Granulosa lutein cells are indicated by the letter G and theca lutein cells by
the letter T. In section d the insert shows a serial section immunostained for
P450C17. Negative control section incubated with non immune serum in place of
primary antibody (e) is free from immunostaining. Tonsil (f) shows immunostaining
for bax in a germinal centre (GC). The bar represents "lOO^m.
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Figure 5.6
SDS-PAGE and immunoblotting for bax throughout the luteal phase. Protein
samples are identified as follows: E, early; M, mid; L, late; R, rescued; T, tonsil. A
single protein band was detected at 21kDa, consistent with bax, throughout the




Polymerase chain reaction for bax throughout the luteal phase.
A 233 base pair cDNA amplimer, consistent with bax, was obtained using c DNA
templates from the early (E), mid (M), late (L), and rescued (R) stages of the luteal
phase.
A 956 base pair fragment consistent with GAPDH, a housekeeping gene, is
amplified at a constant level from corresponding cDNAs confirming that equivalent
quantities of template were used for each reaction.
Negative control PCR mixes were run with sterile water in place of human luteal
cDNA template, no amplimer was observed in the negative control lanes (N).
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IMMUNE CELLS AND LUTEAL FUNCTION
6.1 Introduction
6.1.1 General points
The immune system may be important for the control of luteal structure and
function. In vitro and in vivo studies suggest that immune cells and their
secretory products have the potential to influence steroid production, blood
vessel formation and the balance between cell proliferation and death in the
corpus luteum (reviewed in chapter 1.7).
Although marked species differences exist, significant changes occur in
numbers and distribution of immune cells during luteal maintenance and
regression in non-primate species (Brannstrom and Norman 1993).
Recent studies by Duncan et al (1998) have examined macrophage distribution
during luteal maintenance and regression in women. Macrophage numbers are
significantly lower in hCG treated corpora lutea than in untreated tissue from
the late luteal phase. It is not known whether numbers or distribution of other
immune cell types vary in a similar manner with changing luteal function.
6.1.2 Mediators of changes in cell numbers- MCP-1
Duncan et al (1998) record an attenuation of the increase in macrophage
numbers observed during luteal regression after hCG administration. As hCG
acts through the common LH receptor on steroidogenic cells it is likely that
paracrine mediators are involved. Studies in rat ovary have indicated that MCP-
1, a potent macrophage chemoattractant protein, may be implicated (Townson
et al 1995; 1996). hCG may act directly or by increasing progesterone
production which in turn may down-regulate MCP-1 production (Kelly et al
1997). This would conversely allow secretion of MCP-1 to increase as
progesterone production falls during luteal regression.
MCP-1 is localised in steroidogenic cells of rat corpora lutea (Hosang et al
1994), and expression increases during luteal regression but is attenuated in
early pregnancy (Townson et al 1995; 1996). It is not known whether MCP-1 is
expressed in human corpora lutea or whether secretion follows a similar pattern
during luteal maintenance and regression in women.
6.1.3 Aims of chapter
This chapter aims to supplement the work which already details macrophage
numbers at different stages of luteal function and in luteal rescue (Duncan et al
1998) by identifying the distribution and numbers of immune cell subsets in
women throughout the luteal phase and in simulated early pregnancy. Specific
markers examined will comprise: (a) CD45, an antigen common to leukocytes
which will detect lymphocytes, monocytes, macrophages and granulocytes
(Schwinzer 1989); (b) CD3, a specific marker for T lymphocytes and (c)
neutrophil elastase, which is a marker of neutrophilic granulocytes.
This chapter will also explore potential mechanisms underlying the influx of
macrophages in the late luteal stage by examining the expression of MCP-1 at
different stages of luteal function in women.
6.2 Materials and Methods
6.2.1 Immunohistochemistry for CD45
5^m sections were cut from early (n=6), mid (n=6), late (n=6) and rescued
(n=6) corpora lutea. In addition 5fxm sections of human tonsil were included in
each run to serve as positive control tissue. Sections were dewaxed in xylene
and rehydrated in 100%, 95% and 70% ethanol. Antigen retrieval was
performed by exposing sections to 2 cycles of microwave irradiation at 700w in
citrate buffer 0.01 M pH6.0.
Sections were subsequently blocked with normal horse serum diluted 1:5 in tris
buffered saline (SAPU, Carluke, UK). Monoclonal anti CD45 antibody, raised
against human peripheral blood lymphocytes (Dako, High Wycombe, UK) was
applied at a 1:25 dilution (12|xg/mL) and sections were incubated overnight at
4°C. Negative control sections were incubated with 12^g/mL of non-immune
mouse IgG in place of primary antibody.
After application of biotinylated horse antimouse secondary antibody (Vector,
Peterborough, UK) an avidin/biotin alkaline phosphatase detection system was
used. This reacted with Vector Red chromogen to produce red immunostaining
in CD45 positive cells.
Numbers of CD45 positive cells were counted in four x100 power fields from
each section. In all cases the observer was unaware of the nature of the section
being examined. Preliminary investigations showed that increasing the number
of fields above four did not increase statistical accuracy of the estimations (for
early corpora lutea examination of eight fields per section resulted in a mean of
8 positive cells per field, confidence limits 4-12). Differences in the number of
cells expressing antigen per high power field were investigated by one-way
analysis of variance using stage of the luteal phase as a between subject
(corpus luteum) variable with Fischers PLSD test. The numbers of antigen
expressing cells in late and rescued corpora lutea were also compared in the
same manner.
6.2.2 Immunohistochemistry for neutrophil elastase
Sections were dewaxed and rehydrated as for CD45 immunostaining. Sections
underwent proteolytic digestion in 0.1% trypsin pH7.4 at 37°C for 45 minutes
and were then blocked with horse serum as above.
Monoclonal antibody directed against human neutrophil elastase was applied at
1:50 dilution and sections were incubated at 37°C for 1 hour. Negative control
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sections were incubated with an equivalent concentration of mouse IgG in place
of primary antibody.
As for CD45 staining, an alkaline phosphatase-linked avidin-biotin detection
system was used. Vector Red gave red immunostaining in positive cells.
Numbers of neutrophils were counted in 4 low power (x40) fields in each
section. Examination of more than 4 low power fields was precluded by the size
of the luteal biopsies.
6.2.3 Immunohistochemistry for T cells
5r<,m sections of corpus luteum and tonsil were dewaxed and rehydrated as
described above. Sections were blocked in 3% hydrogen peroxide in distilled
water for 5 minutes, then digested in 0.1% trypsin pH7.4 for 30 minutes at
37°C. A commercial antibody was applied for I hour at 37°C. The commercial
antibody complex used consisted of rabbit anti-T cell CD3 and horse radish
peroxidase coupled to an inert polymer backbone and was supplied ready
diluted (EPOS Anti-human T cell, Dako). Negative control sections were
incubated with EPOS negative control solution. Positive cells were visualised by
application of diaminobenzidine chromogen, giving brown immunostaining in
positive cells.
6.2.4 SDS-PAGE and immunoblotting for MCP-1
Protein was extracted from eight corpora lutea (2 early, 2 mid, 2 late and 2
rescued). Tissue was solubilised in 0.1% SDS buffer at 4°C, sonicated and
centrifuged for 5 minutes. Supernatant was stored in aliquots at -20°C prior to
use. Protein content in the homogenates was determined by Bradford's method
using a commercial kit (Bradford 1976; Biorad, Hercules, CA, USA). For
polyacrylamide gel electrophoresis, 200^g samples were denatured by boiling
for five minutes in an equal volume of sample buffer containing 5% p-
mercaptoethanol and run alongside molecular weight markers (Rainbow
Markers, Amersham International, Buckinghamshire, UK) on an 10%
polyacrylamide gel. Proteins were transferred onto a nitrocellulose membrane
for 18 hours at 50 volts. Western blots obtained (Hybond, Amersham), were
analysed for MCP-1 protein with polyclonal MCP-1 antibody raised in rabbit (gift
of Dr Rodney Kelly, MRC Reproductive Biology Unit, Edinburgh, UK) at 1:250
dilution. Proteins were detected with an avidin/ biotin linked alkaline
phosphatase system which reacted with Vector black chromogen to give brown-
black bands.
6.2.5 PCR and purification of MCP-1 fragment
Total RNA was extracted from eight corpora lutea (2 early, 2 mid, 2 late and 2
rescued) by the method of Chomczynski and Saatchi (1987). The quantity and
purity of the nucleic acid preparations were estimated by measuring the optical
density of each sample at 260 vs. 280nm. Total RNA was reverse transcribed
into first strand cDNA using oligo(deoxythymidine)-primer and MMLV-reverse
transcriptase (Clontech, Palo Alto, CA, USA). Oligonucleotide primers were
synthesised based on the human MCP-1 cDNA sequence (Yoshimura et al
1 989) as follows 5« AATCAATGCCCCAGTCACCTGC 3', and 5'
CGGAGTTTGGGTTTGCTTGTCC 3'. The first strand of cDNA was subjected
to 30 cycles of PCR amplification (1 min denaturation at 94°C, 1 min annealing
at 45°C and 1 minute extension at 72°C) with a final 10 minute extension at
72°C. The amplified products were resolved a 1.5% agarose gels.
In addition to a 210bp band consistent with MCP-1 an unidentified band of
approximately 600bp was identified on the gel. In order to proceed to
subcloning of the MCP-1 fragment, the appropriate band was purified. Gel
bands were visualised under UV light. A sterile 16 gauge hypodermic needle
with attached 2 mL syringe was inserted into the appropriate MCP-1 band and
the plunger was pushed up and down several times in order to draw small
quantities of the gel with appropriate cDNA band into the needle. In order to use
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the small amount of cDNA withdrawn as a template for PCR, the needle and
syringe were then introduced into a 0.5 ml_ PCR tube containing 50f.il of a PCR
mastermix containing dNTPs, MCP-1 primers and taq polymerase. This solution
was aspirated up and down with the syringe and needle a number of times.
This was repeated for MCP-1 cDNA bands from each stage of the luteal phase
which were visible on the original gel.
The mixture was then processed for PCR as above. MCP-1 cDNA selected in
this way was resolved on a 1.5% gel.
6.2.6 Subcloning
The 210bp fragment obtained as above was ligated into pCRII vector and
transformed into competent E-coli cells using a TA cloning kit (Invitrogen,
Carlsbad, CA, USA). Plasmid was extracted with a commercial kit (Wizard
Prep, Promega, Madison, Wl, USA).
In order to check that extracted plasmid contained the insert of interest,
restriction digestion with EcoR1 was carried out. This endonuclease restricts on
either side of the insert in pCRII.
Plasmids underwent sequencing by Mr J Gaughan (MRC Reproductive Biology
Unit) .
6.3 Results.
6.3.1 Immunohistochemistry for CD45
CD45 positive cells were identified in tonsil and in all sections of human corpora
lutea examined. Cells with CD45 immunostaining were present between both
theca and granulosa lutein cells, in the stromal tissue at the periphery of the
gland and in small luteal blood vessels. CD45 positive cells were most
numerous at the junction of the theca and granulosa lutein cells, and in the area
between the granulosa lutein cells and the central cavity. CD45 positive cells
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were also present within the fibrin mass at the centre of the corpus luteum
(figure 6.1).
Numbers of CD45 positive cells varied significantly throughout the luteal phase.
Numbers per low power field were low in the early luteal phase (9, confidence
limits 5-13) rising significantly in the mid luteal phase (38, confidence limits 30-
46, p<0.05) and rising further still to a peak of 61 in the late luteal phase
(confidence limits 44-78). Numbers of CD45 positive luteal cells fell significantly
following hCG treatment to 22 (confidence limits 15-29, p<0.05) (figure 6.2).
6.3.2 Immunohistochemistry for neutrophil elastase
Cells staining positively for neutrophil elastase were present in human tonsil
and in all sections of human corpora lutea examined. Neutrophils, although
present, were scarce, and were localised in the granulosa cell layer, the theca
cell layer and in the stroma surrounding the gland. Neutrophils were most
commonly observed as small clusters, often within small blood vessels in each
of the layers described (figure 6.3).
Due to large variations within each of the early, mid, late and rescued luteal
groups, numbers of neutrophils did not change significantly throughout the
luteal phase. However a trend in neutrophil numbers was observed, with higher
numbers observed in the early (33, confidence limits 11-55) and late (37,
confidence limits 18-56) corpora lutea, and lower numbers observed in the mid
(6, confidence limits 3-9) and rescued corpora lutea (4, confidence limits 1-7).
The fall in neutrophil numbers following hCG treatment did not reach statistical
significance (p=0.31) (figure 6.4).
6.3.3 Immunohistochemistry for CD3
Immunostaining for CD3 was observed in tonsil, used as a positive control
tissue. CD3 positive cells were extremely sparse in the human corpus luteum
(less than 5 positive cells per section) and were only observed in 50% of
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sections. When present, T cells were most commonly located in larger blood
vessels or the stroma surrounding the gland. T cells were not observed in
granulosa ortheca lutein cell layers (figure 6.5). Numbers of T cells did not vary
significantly throughout the luteal phase or in simulated early pregnancy.
6.3.4 SDS-PAGE and immunoblotting for MCP-1
Immunoblotting for MCP-1 revealed 3 faint bands at 14 kDa, 18 kDa and 32
kDa. The smallest of these bands is consistent with published reports of MCP-1
in other tissues (Yoshimura et al 1989), while the larger bands may correspond
to a glycosylated form of the cytokine or to MCP-1 dimer formation.
The 14 and 18 kDa bands were present throughout the luteal phase and during
simulated early pregnancy (figure 6.6).
6.3.5 PCR and purification of MCP-1 fragment
Initial PCR for MCP-1 resulted in the amplification of 2 fragments of cDNA, a
smaller 210bp fragment, corresponding to MCP-1, and a larger 600bp
fragment. MCP-1 and the larger unidentified fragment were detected in corpora
lutea from all stages of the luteal phase (figure 6.7).
After inoculation of a new PCR mix and subsequent amplification, a single
210bp band was obtained in all four reactions (figure 6.7).
6.3.6 Subcloning and sequencing of MCP-1
Restriction digestion with EcoR1 showed that a 210bp fragment had been
successfully cloned into the pCRII vector. Sequencing revealed that the plasmid




This is the first study to demonstrate the presence of MCP-1 in the human
corpus luteum. In addition, this work represents the first description of luteal
leukocyte, neutrophil and T cell distribution in simulated early pregnancy in
women.
6.4.2 Changes in leukocyte numbers throughout the luteal phase
In agreement with previous studies, number of white blood cells was shown to
increase during functional luteal regression (Brannstrom et al 1994a) This
investigation has demonstrated that this influx of leukocytes is prevented by
hCG treatment. With no significant change in numbers of neutrophils or T
lymphocytes at different stages of luteal function it is likely that the changes in
white cell numbers are largely due to variations in macrophage numbers.
Although changes in neutrophil numbers throughout the luteal phase did not
reach significance there was a trend for greater numbers of these cells in the
early and late luteal phases. In other species, an influx of neutrophils has been
noted at the time of ovulation (Gerdes et al 1992; Brannstrom et al 1993), and it
has been suggested that the ability of these cells to break down the
extracellular matrix may contribute to tissue remodelling associated with
formation of the corpus luteum (Behrman et al 1993).
Neutrophils have also been implicated in luteal regression in the rat. When
incubated with luteinised granulosa cells, neutrophils were associated with a
decrease in progesterone secretion (Peperell et al 1992). Neutrophils are
capable of free radical production, which has been linked to their luteolytic
action in vitro (Behrman and Preston 1989; Brannstrom and Norman 1993).
The ability of neutrophils to breakdown the extracellular matrix is likely to be of
importance in structural luteal regression, but may also be important for
angiogenesis throughout the lifespan of the gland.
T cells were not abundant in the human corpus luteum at any stage of function.
Lymphocytes secrete cytokines which have been demonstrated to posses
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luteotropic properties in vitro (Emi et al 1991). However no increase in T cell
abundance was observed after treatment with hCG to simulate early
pregnancy.
6.4.3 Increased leukocyte numbers in luteolysis- potential mechanisms
The increase in numbers of leukocytes during luteal regression may be due to
recruitment of white cells from the blood stream and subsequent migration into
the gland under the influence of locally produced chemotactic factors.
Alternatively macrophages already present in the corpus luteum may proliferate
shortly before or during luteolysis. A cohort of proliferating non-endothelial, non
steroidogenic cells have been identified in the human corpus luteum (Rodger et
al 1997). It is possible that proliferating immune cells contribute to this subset
of dividing cells. However, the proliferating non-endothelial non-steroidogenic
cells were morphologically similar to steroidogenic cells and shared none of the
morphological characteristics of macrophages or neutrophils, the two most
prevalent types of human luteal white cells.
Recruitment of leukocytes from the bloodstream involves attachment to the
vascular wall, passage between endothelial cells and subsequent migration into
the gland ). Each of these processes could be observed in CD45 positive cells
in the corpus luteum (figure 6.8). These processes may be facilitated by
cytokines such as IL-1 and TNFa secreted from immune or steroidogenic cell
compartments.
6.4.4 MCP-1 and changing luteal function
MCP-1 was identified in the human corpus luteum by PCR and subcloning, and
SDS-PAGE and immunoblotting. MCP-1 was detected at all stages of the luteal
phase with no stage dependent changes in MCP-1 levels observed. This finding
contrasts with data obtained from the rat corpus luteum (Townson et al 1995;
1996) which suggest that levels of MCP-1 increase during luteal regression.
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There are considerable species differences in the distribution and production of
other cytokines in the corpus luteum (Brannstrom and Norman 1993), and
MCP-1 may have a varying involvement in the control of luteal function in
different species.
In the human other local mediators may be involved in macrophage recruitment
during luteal regression. Constant levels of MCP-1 in the gland may maintain
the baseline numbers of macrophages which may be essential for the function
of the gland throughout the luteal phase. MCP-1 also has angiogenic properties
(Nakashima et al 1995; Ito et al 1997) and may be involved in the high level of
angiogenesis which is typical of the corpus luteum.
6.4.5 Other steroidogenic cell cytokines
Steroidogenic luteal cells may also secrete factors which are chemotactic for
other subgroups of immune cells, lnterleukin-8 has neutrophil chemoattractant
and activating properties in vitro and in vivo (Baggiolini et al 1989) and has
recently been identified in human luteinised granulosa cells (Arici et al 1996).
Production of this cytokine is negatively regulated by progesterone in a similar
way to MCP-1 (Arici et al 1996), but it is unclear whether production of this
cytokine controls the ingress of neutrophils in the corpus luteum. IL-8 also has
angiogenic properties (Koch et al 1992) and may be associated with control of
the luteal vasculature.
6.4.6 The immune system may have a broad role in the control of luteal
function
As well as a role in structural luteal regression, leukocytes may have an
integral role in wider aspects of luteal function (Alila and Hansel 1984). Cells of
the immune system may have luteotropic as well as luteolytic effects
(Brannstrom and Norman 1993), and secretory products of white blood cells
may alter rates of proliferation and apoptosis in the corpus luteum as well as
influencing luteal angiogenesis.
Where leukocytes are involved in luteal regression, this may be by means of
phagocytosis, free radical production or extracellular matrix remodelling.
6.4.7 Overview
This chapter has highlighted the interactions between cells of the immune,
endothelial and steroidogenic cell compartments in luteal function. Increased
numbers of white blood cells may be involved in luteal regression, but lower
numbers of immune cells may be required for optimal luteal function earlier in
the lifespan of the gland.
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Figure 6.1
Immunostaining for CD45 (common leukocyte antigen in the human corpus
luteum). Leukocytes are present in early (a), mid (b), late (c) and rescued (d)
corpora lutea. The insert shows a negative control section which was incubated
with non-immune mouse IgG in place of primary antibody and is free from




Graph illustrating numbers of CD45 positive leukocytes per x 100 field
throughout the luteal phase and in simulated early pregnancy. Numbers of
leukocytes increase significantly in the late luteal phase. Treatment with hCG is
associated with a significant reduction in leukocyte numbers.
Leukocyte numbers throughout the luteal phase
80 -|
early mid late rescued
stage of luteal phase
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Figure 6.3
Immunostaining for neutrophil elastase in the human corpus luteum and tonsil.
Low power view of immunostaining for neutrophil elastase in early corpus
luteum (a) with corresponding negative control (b). High power view of a
peripheral vessel in the early corpus luteum immunostained for neutrophil
elastase (c) with corresponding negative control (d). Negative controls were
incubated with mouse IgG in place of primary antibody. Immunostaining for
neutrophil elastase in human tonsil, used as a positive control tissue, is shown




Graph illustrating numbers of neutrophils per low power (x40) field throughout
the luteal phase and in simulated early pregnancy. There are no significant
differences in neutrophil numbers at different stages of luteal function.
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Figure 6.5
Immunostaining for CD3 (T cells) in the human corpus luteum and tonsil.
Immunostaining is abundant in tonsil, used as a positive control tissue. T cells
in a section of late corpus luteum are shown in (b) (arrow). Lack of T cell
staining in the granulosa cell layer of a rescued corpus luteum is demonstrated




SDS-PAGE blotting for MCP-1 in the human corpus luteum throughout the
luteal phase. Protein samples are delineated as early, mid, late and rescued.
Protein bands, consistent with MCP-1, are present at 14 and 18kDa.
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Figure 6.7
(a) Initial PCR for MCP-1 at different stages of luteal function. A 210 base pair
band consistent with MCP-1 is observed at all stages of luteal function but in
several samples a larger unidentified 600 base pair fragment is visible.
(b) Purification of MCP-1 band from gel. After inoculation of a PCR mix with the
appropriate band, a single cDNA band of 210 base pair band consistent with
MCP-1 is amplified throughout the luteal phase.





PCR of purified MCP-1 fragment
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Figure 6.8
Immunostaining for CD45 illustrates recruitment of leukocytes from the
bloodstream into the corpus luteum. The leukocyte first attaches to the wall of
the blood vessel (a) then passes between the endothelial cells (b) to enter the
luteal parenchyma (c). All sections are from the same early corpus luteum, and
in each case the magnification bar represents 25nm.
 
CHAPTER 7
DISCUSSION: SIGNIFICANCE OF NON-STEROIDOGENIC CELLS IN
LUTEAL MAINTENANCE AND REGRESSION
7.1 Summary of results
This thesis has aimed to examine the relative roles of different cellular
mechanisms in controlling luteal lifespan. Endothelial, immune and
steroidogenic cell pathways have been examined throughout the luteal phase.
In addition, rates of cell growth and expression of apoptotic proto-oncogenes
have been studied. The work described in this thesis has led to speculation that
interactions between cells of more than one lineage may regulate luteal
function.
The results of these investigations can be summarised as follows:-
1. Cell proliferation is maximal during formation of the corpus luteum, but
changing proliferation rates are not associated with luteal rescue in early
pregnancy or with luteal regression at the end of a cycle. Endothelial cells
represent the main proliferating cell compartment in the human corpus
luteum, and steroidogenic cells rarely proliferate.
2. VEGF and bFGF are produced by steroidogenic and endothelial cells
respectively throughout the lifespan of the corpus luteum and are
produced at constant levels during changes in luteal function. These
factors may play a major role in supporting angiogenesis in the human
corpus luteum.
3. While apoptosis has been described in the corpus luteum and may be
involved in luteal regression, expression of bcl-2 and bax, proto-oncogenes
which control apoptotic rates in ovarian follicles and other tissues, do not
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change throughout the lifespan of the corpus luteum, in simulated early
pregnancy or luteal regression.
4. The largest compartment of immune cells in the corpus luteum is
macrophages, but neutrophils and T cells are also present. Total leukocyte
numbers are highest during luteolysis and it has been proposed that such
cells may be involved in the structural and functional regression of the
gland. The human corpus luteum produces MCP-1 which is chemotactic for
macrophages. MCP-1 is produced throughout the luteal phase in women.
7.2 The experimental model used : strengths and weaknesses
7.2.1 Description of experimental model used
The investigations described in this study were performed with tissue from an in
vivo model of human luteal function. In contrast, much of current understanding
of human luteal physiology is based on investigations utilising in vitro luteal
systems, in particular luteinised granulosa cells.
The experimental model developed for this thesis involved retrieval and
characterisation of luteal biopsies from women undergoing hysterectomy for
benign gynaecological disorders. Luteal tissue was accurately dated by clinical
and endocrinological parameters. To investigate luteal physiology during
simulated early pregnancy a cohort of women received treatment with an
incremental regime of hCG which has previously been shown to mimic the
endocrine effects of early pregnancy (lllingworth et al 1990).
7.2.2 Strengths of model
This in vivo-model of luteal formation, regression and maintenance confers a
number of advantages over in vitro methodology.
Although in vitro studies have yielded data describing steroidogenic cell
function under varying conditions, these systems may not accurately represent
the physiological processes which occur throughout the luteal lifespan. In such
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in vitro systems granulosa cells retrieved from ovarian follicles luteinise in vitro.
They are thus isolated from the mechanical and secretory influences of
endothelial and immune cells with which they would be in close contact in vivo.
Moreover, nutrients and tropic factors are present at regulated levels in culture
media of in vitro systems. The physiology of luteal tissue in vivo is however
likely to be influenced by variable local factors such as vascular supply and
permeability, secretion of growth factors and production of non-secreted factors
such as free radicals.
The in vivo model used in this thesis confers a number of additional advantages
over in vitro systems.
This model used human luteal tissue. Marked species differences in luteal
structure and function occur across domestic species and primates.
Examination of human luteal tissue is therefore important to clarify the distinct
processes which may control luteal lifespan in our species.
The system of tissue collection utilised in this study ensured that luteal tissue
was retrieved prior to ligation of the ovarian vasculature and that tissue was
fixed or frozen immediately on retrieval from the patient. This contrasts with
other investigators who have examined corpora luteafrom routine pathology
specimens. Such routine specimens will have been devoid of vascular support
for 30 to 60 minutes prior to fixation or freezing. This may lead to increased
expression of hypoxia-sensitive gene products and is a possible source of
artefact.
This collection system utilised in this thesis formed a luteal tissue bank
containing over 60 luteal biopsies from differing stages of luteal function. This
permitted examination of adequate numbers of identically fixed and processed
and frozen corpora lutea at each stage of the luteal phase.
The experimental model of human luteal function used in this thesis allowed the
examination of luteal physiology in intact tissue at a wide range of time points
throughout the luteal phase. As individual cell types were not separated, the
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importance of steroidogenic and non-steroidogenic ceil types and their
interactions at times of changing luteal function could be evaluated. Limited
manipulation of the system was possible, and administration of hCG to prolong
luteal function allowed comparison of luteal maintenance and regression.
7.2.3 Limitations of model
Although this in vivo model allowed examination of the physiology of the corpus
luteum as a whole throughout its lifespan, results obtained from these
investigations must be considered with reference to the limitations of the
experimental model used.
The experimental model utilised tissue retrieved from donors of older
reproductive age (median age 40 years). However all luteal donors
demonstrated midcycle urinary LH peaks and all subjects had ovulatory
progesterone concentrations apart from the late luteal group where the low
concentration would be anticipated. In addition Klein et al (1996) has shown
that while older women have marked differences in early phase FSH and
inhibin B concentrations compared with younger women, there is no difference
in the function of either the dominant follicle or the corpus luteum.
It is therefore unlikely that the older reproductive age of the luteal donors would
affect the appropriateness of the tissue studied.
Early pregnancy was simulated by an increasing regime of hCG administration
in a cohort of luteal donors. hCG stimulation was continued for 6 to 8 days prior
to luteal retrieval. This regime has previously been shown to closely mimic the
endocrine effects of early pregnancy in terms of serum levels of progesterone
and inhibin, but the regime may have important limitations. The short duration
of hCG stimulation may give rise to an initial increase in endocrine output of the
corpus luteum without allowing time for more complex functional and structural
events associated with maternal recognition of pregnancy to occur. Similarly,
retrieval of late luteal biopsies was carried out on days 10-14 after ovulation,
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and no luteal biopsies were obtained after menstruation had commenced. Initial
attempts to remove corpora lutea in the follicular phase of the next ovarian
cycle were unsuccessful due to the friable nature of the structurally regressing
gland.
It is possible that levels of endothelial cell proliferation and angiogenic growth
factor production observed during luteal maintenance and regression in our
model undergo changes at later time points during luteal maintenance and
regression than examined using this model. Similarly, changing ratios of the
apoptotic proto-oncogenes bcl-2 and bax may not be observed at the early time
points examined.
Alternatively, it is possible that currently unknown extraovarian factors are
important for luteal maintenance. If this was the case then hCG stimulation
alone may not give an accurate representation of the changes occurring during
physiological luteal rescue. However no such factors have been identified, and
as mentioned previously, hCG administration is associated with changes in
luteal secretion identical to those described in early pregnancy (lllingworth et al
1990).
The model used allows description of processes occurring throughout the luteal
phase, but provided the opportunity for only limited manipulation of luteal
function. In future studies it may be possible to examine human luteal
physiology during induced luteal regression by administration of luteolytic
agents to donors prior to tissue retrieval. Alternatively the role of the luteal
vasculature could be examined by administration of angiogenesis inhibitors or
angiogenic growth factor antagonists prior to tissue retrieval. Ethical issues
prevent the use of such compounds in human luteal donors at present, and
data obtained in this study are essentially descriptive.
7.2.4 Contribution of model to work in the field
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The work detailed in this thesis utilising an in vivo model of human luteal
function represents a significant contribution to the field. An in vivo model of
human luteal function has been developed and a large luteal tissue bank has
been established, allowing description of processes involving non-steroidogenic
as well as steroidogenic cells throughout the luteal lifespan.
7.3 Advances in the field during the course of these studies.
During the course of these investigations other workers have provided data
complementary to our own.
7.3.1 Advances- luteal angiogenesis
Several studies have combined immunohistochemical techniques for the
detection of proliferating cells and endothelial cells in order to investigate extent
of angiogenesis in the corpus luteum.
Studies in the corpus luteum of the rhesus macaque (Christenson and Stouffer
1996) agree with our observation that proliferating endothelial cells are most
abundant in the developing corpus luteum. Angiogenesis continues in the
macaque at a lower level until a further decline at the end of the luteal phase. In
parallel with our studies in the human corpus luteum hCG treatment had no
effect on the level of luteal angiogenesis in the macaque. Christenson and
Stouffer detected no proliferating steroidogenic cells in the rhesus monkey at
any stage of luteal function, including simulated early pregnancy.
Vascular growth has been examined in the non-pregnant human corpus luteum
(McClure et al 1994). In contrast to our data a fall in endothelial cell proliferation
was noted during the last five days of the cycle. These authors conclude that
luteal regression may be associated with declining rates of angiogenesis. The
differing results may be due to the use of antibody directed against PCNA
(proliferating cell nuclear antigen) to identify proliferating cells by these workers.
This antibody has previously been shown to be less specific for the
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identification of proliferating cells than the Ki67 used by our group (Boulton and
Hodgson 1995). No other workers have examined the effects of hCG treatment
on angiogenesis in the human.
7.3.2 Advances- luteal angiogenic factors
During the course of the experimental work described in this thesis VEGF
expression has been examined in the corpora lutea of several species.
Surprisingly, it would appear that there are marked differences in VEGF
localisation and expression between species.
In ovine corpora lutea, VEGF is localised in perivascular areas (Redmer et al
1996), whereas in primates VEGF is produced in steroidogenic cells
(Ravindranath et al 1992b; Gordon et al 1996; Kamat et al 1995). VEGF
production in ovine corpora lutea is maximal during luteal formation, but does
not decrease significantly during functional luteal regression (Redmer et al
1996). VEGF production is also maximal in the early luteal phase in monkeys
(Ravindranath et al 1992b) and women (Kamat et al 1995; Gordon et al 1996)
but during luteal regression a significant decrease is not noted until the onset of
menses.
The importance of blood vessel formation in murine corpora lutea has been
examined using AGM-470, an analogue of fumagillin with well characterised
anti-angiogenic activity (Klauber et al 1997). AGM-1470 inhibits endothelial cell
proliferation at concentrations which do not affect other cell types, and is potent,
highly selective and non toxic. A single injection of AGM-1470 caused no
decrease in serum progesterone and did not affect luteal morphology in
pregnant mice. However, chronic treatment of non-pregnant rats with AGM-
1470 results in a significant decrease in the size and number of corpora lutea in
comparison with control animals. This implies that sustained angiogenesis is
necessary for normal luteal development in the mouse.
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Changing levels of angiogenic factors may affect blood vessel formation and
the vascular supply of the corpus luteum, which in turn may influence luteal
regression and maintenance. Further studies using specific bFGF and VEGF
inhibitors are required to elucidate the role of these growth factors.
Angiogenesis in a variety of tissues is thought to be controlled by the production
of angiogenic and antiangiogenic factors (Zagzag 1995; Shifren et al 1994;
Wheeler et al 1995; Folkman 1995). No antiangiogenic factors have yet been
detected in corpora lutea of any species but it is possible that these may also
control luteal angiogenesis.
7.3.3 Advances - apoptosis
Understanding of the bcl-2 family of proto-oncogenes has expanded since the
outset of this work, when bcl-2 and bax had been characterised and no other
bcl-2 family members had been identified. During the course of the
investigations it became apparent that bcl-2 and bax were only two members of
a diverse family of structurally and functionally related proto-oncogenes. The
first of these additional proto-oncogenes, bcl-x, was isolated by hybridisation to
a bcl-2 probe. The bcl-x gene is alternatively spliced to produce at least two
species of mRNA and protein (Boise et al 1993). Bcl-x long is highly
homologous to bcl-2 and also is antiapoptotic. Bcl-x short is 63 amino acids
smaller that bcl-x long and has the opposite effect by inducing apoptosis.
There are numerous other members of the bcl-2 family which may interact with
one another to alter the rate of cell death. They include bak, mcl-1 bag, bad and
A-1 (Farrow et al 1995; Kozopas et al 1993; Chittenden et al 1995; Lin et al
1993; Tilly 1996).
Work from other groups supports the hypothesis that bcl-2 family members may
influence apoptosis in the corpus luteum. Bax has been identified in murine
corpus luteum by immunoblotting but its cellular location within the gland is
unknown (Krajewski et al 1994a). Bax expression is upregulated during
structural regression in bovine corpora lutea (Rueda et al 1997) but there are
no descriptions of bax in the primate corpus luteum or in early pregnancy in any
species. Mcl-1 has been immunolocalised in human granulosa lutein cells and
bcl-x in theca lutein cells of murine corpora lutea (Krajewski et al 1994b).
Expression of these proto-oncogenes at different stages of luteal function has
not been described.
In order to elucidate the role that the bcl-2 family may play in regulation of luteal
function we first require better understanding of interactions between the bcl-2
family members.
7.3.4 Advances- immune system
Upregulation of MCP-1 has been shown in association with macrophage influx
during structural luteal regression in rats (Townson et al 1995; 1996). Recent
work has demonstrated that MCP-1 production in women is inhibited by
physiological levels of progesterone (Kelly et al 1997). It is possible that
declining local progesterone levels during functional luteal regression allow
upregulation of MCP-1 production. This may in turn trigger the influx of
macrophages typically seen during structural luteal regression.
The immunoblotting and PCR studies described in this thesis have not shown
significant changes in MCP-1 expression or production during functional luteal
regression or maintenance. Although it is possible that the mechanism of
macrophage recruitment during structural luteal regression exhibits species
variation, techniques which benefit from increased sensitivity and localisation
are required to further define MCP-1 expression in the human corpus luteum.
7.4 Role of the corpus luteum in the female reproductive system
The human corpus luteum is essential for human fertility.
During luteal formation and function secretion of progesterone into the
bloodstream allows preparation of the endometrium for the implanting
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blastocyst. In a fertile cycle, continuing progesterone secretion is essential for
maintenance of the pregnancy until placental steroidogenesis later assumes
this function. In the absence of a functioning corpus luteum pregnancy will not
be maintained unless supported with exogenous progesterone.
In addition to this essential role in the maternal recognition of pregnancy, the
corpus luteum is also an important controller of the hypothalamic pituitary
ovarian axis in women. Steroid hormones secreted by the corpus luteum feed
back at hypothalamic and pituitary levels to suppress FSH secretion and
follicular development during the luteal phase. In a non-conception cycle falling
levels of these factors at luteal regression allow resumption of FSH secretion
and a new wave of folliculogenesis occurs. In order to fulfill these important
roles in the regulation of human fertility the corpus luteum must develop from
the dominant follicle in a short space of time, maintain a large biosynthetic
capacity throughout its lifespan, be efficiently rescued in fertile cycles, and
regress when conception has not occured.
7.4.1 Luteal formation
Preparation for secretion of large amounts of progesterone occurs in women
prior to ovulation, with changes in the endocrinology of the dominant follicle
detectable a few hours after the LH peak. The outer cells of the granulosa layer
no longer convert androgen to oestrogen but instead synthesise progesterone.
LH stimulates this progesterone synthesis via newly acquired LH receptors on
these cells. Following ovulation a critical event in luteinisation is the invasion of
the granulosa cell layer by thecal blood vessels which supply the substrates
and energy necessary for progesterone biosynthesis. The development of a
dense network of blood vessels to supply the steroidogenic cells of the newly
formed corpus luteum is associated with strikingly high rates of angiogenesis in
the gland at this time. Steroidogenic cells may control rates of luteal
angiogenesis by secretion of paracrine factors such as VEGF, and rates of cell
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death in the endothelial cell compartments may be low as the vasculature of the
gland is established. Cytokine products of immune cells, which invade the
follicle at ovulation (Brannstrom and Norman 1993) may influence rates of luteal
steroidogenesis, angiogenesis or apoptosis during luteinisation.
7.4.2 Luteal regression.
Luteal regression is essential for the return of ovarian cyclicity in a non-fertile
cycle, and is characterised by decreasing production of steroid and protein
hormones, followed by structural regression of the gland.
In women luteal regression occurs in the absence of hCG. This contrasts with
domestic species where luteal regression is triggered by secretion of PGF2a
from the uterus. No such endocrine factor exists in women, and no luteolytic
paracrine mediators responsible for luteolysis have been identified in human
corpora lutea.
It is possible that the relatively low levels of LH which are present in the human
luteal phase are insufficient to maintain the corpus luteum unless hCG
stimulation is present. In the absence of sufficient gonadotrophin stimulation at
the end of the luteal phase steroidogenesis may decline.
Following these initial functional regressive changes, the structure of the gland
also regresses.
Functional luteal regression may also be augmented by the influx of immune
cells into the gland at the end of the luteal phase. Increasing numbers of luteal
immune cells may be due to secretion of chemotactic factors by steroidogenic
cells during luteolysis. Immune cells may influence steroidogenesis by secretion
of cytokine products or by direct cytotoxicity. In addition the decreased local
blood flow noted during luteolysis (Bourne et al 1996) may result in a reduction
of steroidogenic substrate availability. The studies described in this thesis
detect no decrease in vascular density or luteal angiogenesis during functional
luteal regression and changes in vascular tone may be responsible for changes
in luteal blood flow at this stage.
The size of the corpus luteum decreases during structural luteal regression
(Zheng et al 1994). Programmed cell death has been implicated in luteolysis by
studies utilising morphological and 3' end labelling techniques (Funayama et al
1996; Shikone et al 1996). Constant levels of bcl-2 and bax at this stage imply
that mechanisms involved in luteolysis are dissimilar to those implicated in
follicular atresia.
7.4.3 Luteal rescue
Secretion of progesterone by the human corpus luteum is a critical trigger for
the maintenance of early pregnancy. Maintenance of progesterone secretion
from the corpus luteum is dependant on hCG stimulation to prevent functional
and stuctural luteolysis.
After stimulation by hCG luteal production of progesterone, oestrogen and
inhibin increase (lllingworth et al 1990) and the size and vascular flow to the
gland also increase (Alcazar et al 1996). Similar processes have been
described during formation of the corpus luteum after ovulation. In contrast to
the process of luteinisation the vascularity of the gland remains constant and
angiogenic rates do not increase during luteal rescue. Similarly, production of
angiogenic growth factors remains constant during early pregnancy. Distinct
physiological processes occur during hCG stimulation in early pregnancy and
during luteinisation following the LH surge.
As proliferation rates do not increase after hCG rescue of the corpus luteum it is
possible that increased size of the gland may be due to hypertrophy of existing
cells or to decreased rates of apoptosis. Bcl-2/bax ratios remain unchanged
during luteal rescue and apoptosis may be influenced by changes in secretion
of local mediators from steroidogenic or immune cells.
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Immune cells are significantly less abundant in the rescued corpus luteum than
during luteolysis. Lower densities of luteal macrophages in early pregnancy
may remove cytokine blocks to steroid production and prevent destruction of
luteal tissue.
The initial maintenance of function of the corpus luteum may be due to a direct
action of hCG acting through steroidogenic cell LH receptors resulting in
stimulation of progesterone biosynthesis and support of the intrauterine
pregnancy. Later events in luteal maintenance may involve non-steroidogenic
cells with changes in vascularity and growth factor secretion. The structure of
the gland may be preserved by reduction of luteal cell death rates and by
prevention of immune cell chemotaxis in the presence of hCG and
progesterone.
7.5 Overview
The in vivo model of luteal function utilised in this work gives a unique insight
into the possibility that the interactions between steroidogenic, immune and
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